Document:

Exhibit 4.1

  

SKYLINE MEDICAL INC. (f/k/a BIODRAIN
MEDICAL, INC.)

AMENDED AND RESTATED
2012 STOCK INCENTIVE PLAN

 

TABLE OF CONTENTS

 

	1.	 	Purpose	 	1
	 	 	 	 	 	 
	2.	 	Administration	 	1
	 	 	 	 	 	 
	3.	 	Eligible Participants	 	1
	 	 	 	 	 	 
	4.	 	Types of Incentives	 	1
	 	 	 	 	 	 
	5.	 	Shares Subject to the Plan	 	2
	 	 	5.1.	Number of Shares	 	2
	 	 	5.2.	Cancellation	 	2
	 	 	5.3.	Type of Common Stock	 	2
	 	 	5.4.	Limitation on Certain Grants	 	2
	 	 	 	 	 	 
	6.	 	Stock Options	 	2
	 	 	6.1.	Price	 	2
	 	 	6.2.	Number	 	2
	 	 	6.3.	Duration and Time for Exercise	 	3
	 	 	6.4.	Manner of Exercise	 	3
	 	 	6.5.	Incentive Stock Options	 	3
	 	 	 	 	 	 
	7.	 	Stock Appreciation Rights	 	4
	 	 	7.1.	Price	 	4
	 	 	7.2.	Number	 	4
	 	 	7.3.	Duration	 	4
	 	 	7.4.	Exercise	 	5
	 	 	7.5.	Issuance of Shares Upon Exercise	 	5
	 	 	 	 	 	 
	8.	 	Stock Awards, Restricted Stock and Restricted Stock Units	 	5
	 	 	8.1.	Number of Shares	 	5
	 	 	8.2.	Sale Price	 	5
	 	 	8.3.	Restrictions	 	6
	 	 	8.4.	Enforcement of Restrictions	 	6
	 	 	8.5.	End of Restrictions	 	6
	 	 	8.6.	Rights of Holders of Restricted Stock and Restricted Stock Units	 	6
	 	 	8.7.	Settlement of Restricted Stock Units	 	7
	 	 	8.8.	Dividend Equivalents	 	7

 

	 

    	 

    	 

    

  

	 	 	 	 	 	 
	9.	 	Performance Awards	 	7
	 	 	9.1.	Performance Conditions	 	7
	 	 	9.2.	Performance Awards Granted to Designated Covered Employees	 	7
	 	 	9.3.	Written Determinations	 	9
	 	 	9.4.	Status of Performance Awards Under Code Section 162(m)	 	9
	 	 	 	 	 	 
	10.	 	General	 	9
	 	 	10.1.	Plan Effective Date and Shareholder Approval; Termination of Plan	 	9
	 	 	10.2.	Duration	 	9
	 	 	10.3.	Non-transferability of Incentives	 	10
	 	 	10.4.	Effect of Termination or Death	 	10
	 	 	10.5.	Restrictions under Securities Laws	 	10
	 	 	10.6.	Adjustment	 	11
	 	 	10.7.	Incentive Plans and Agreements	 	11
	 	 	10.8.	Withholding	 	11
	 	 	10.9.	No Continued Employment, Engagement or Right to Corporate Assets	 	11
	 	 	10.10.	Payments Under Incentives	 	12
	 	 	10.11.	Amendment of the Plan	 	12
	 	 	10.12.	Amendment of Agreements for Incentives; No Repricing	 	12
	 	 	10.13.	Vesting Upon Change In Control	 	12
	 	 	10.14.	Sale, Merger, Exchange or Liquidation	 	14
	 	 	10.15.	Definition of Fair Market Value	 	15
	 	 	10.16.	Definition of Grant Date	 	16
	 	 	10.17.	Compliance with Code Section 409A	 	16
	 	 	10.18.	Prior Plan	 	17

 

    	2

    	 

    

 

SKYLINE MEDICAL INC. (f/k/a BIODRAIN
MEDICAL, INC.)

AMENDED AND RESTATED 2012 STOCK INCENTIVE
PLAN

 

1.                 
Purpose. The purpose of the Amended and Restated 2012 Stock Incentive Plan (the “Plan”) of Skyline Medical
Inc. (f/k/a BioDrain Medical, Inc.) (the “Company”) is to increase shareholder value and to advance the interests
of the Company by furnishing a variety of economic incentives (“Incentives”) designed to attract, retain and motivate
employees, certain key consultants and directors of the Company. Incentives may consist of opportunities to purchase or receive
shares of Common Stock, $0.01 par value, of the Company (“Common Stock”) or other incentive awards on terms determined
under this Plan.

 

2.                 
Administration. The Plan shall be administered by the board of directors of the Company (the “Board of Directors”)
or by a stock option or compensation committee (the “Committee”) of the Board of Directors. The Committee shall consist
of not less than two directors of the Company and shall be appointed from time to time by the Board of Directors. Each member of
the Committee shall be (a) a “non-employee director” within the meaning of Rule 16b-3 of the Securities Exchange Act
of 1934 (including the regulations promulgated thereunder, the “1934 Act”) (a “Non-Employee Director”),
and (b) shall be an “outside director” within the meaning of Section 162(m) under the Internal Revenue Code of 1986,
as amended (the “Code”) and the regulations promulgated thereunder (“Code Section 162(m)”). The Committee
shall have complete authority to award Incentives under the Plan, to interpret the Plan, and to make any other determination which
it believes necessary and advisable for the proper administration of the Plan. The Committee’s decisions and matters relating
to the Plan shall be final and conclusive on the Company and its participants. If at any time there is no stock option or compensation
committee, the term “Committee”, as used in the Plan, shall refer to the Board of Directors.

 

3.                 
Eligible Participants. Officers of the Company, employees of the Company or its subsidiaries, members of the Board of Directors,
and consultants or other independent contractors who provide services to the Company or its subsidiaries shall be eligible to receive
Incentives under the Plan when designated by the Committee. Participants may be designated individually or by groups or categories
(for example, by pay grade) as the Committee deems appropriate. Participation by officers of the Company or its subsidiaries and
any performance objectives relating to such officers must be approved by the Committee. Participation by others and any performance
objectives relating to others may be approved by groups or categories (for example, by pay grade) and authority to designate participants
who are not officers and to set or modify such targets may be delegated.

 

4.                 
Types of Incentives. Incentives under the Plan may be granted in any one or a combination of the following forms: (a) incentive
stock options and non-statutory stock options (Section 6); (b) stock appreciation rights (“SARs”) (Section 7); (c)
stock awards (Section 8); (d) restricted stock (Section 8); restricted stock units (Section 8) and performance awards (Section
9). Subject to the specific limitations provided in this Plan, payment of Incentives may be in the form of cash, Common Stock or
combinations thereof as the Committee shall determine, and with such other restrictions as it may impose.

 

5.                 
Shares Subject to the Plan.

 

5.1.           
Number of Shares. Subject to adjustment as provided in Section 10.6, the number of shares of Common Stock which may be issued
under the Plan shall not exceed 100,000,000 shares of Common Stock. In addition, as of the Effective Date, any shares available
in the reserve of the Prior Plan (as defined in Section 10.18) shall be added to the Plan share reserve and be available for issuance
under the Plan. Any Shares delivered under the Plan may consist, in whole or in part, of authorized and unissued shares or treasury
shares. Shares of Common Stock that are issued under the Plan or are subject to Incentives awarded under the Plan will be applied
to reduce the maximum number of shares of Common Stock remaining available for issuance under the Plan.

 

5.2.           
Cancellation. If an Incentive granted under the Plan or under the Prior Plan expires or is terminated or canceled unexercised
as to any shares of Common Stock or forfeited or reacquired by the Company pursuant to rights reserved upon issuance thereof, such
forfeited and reacquired shares may again be issued under the Plan pursuant to another Incentive. If any Shares subject to an Incentive
granted under the Plan or under the Prior Plan are withheld or applied as payment in connection with the exercise of an Incentive
(including the withholding of Shares on the exercise of a stock option or the exercise of an SAR that is settled in Shares) or
the withholding or payment of taxes related thereto, such Shares shall not again be available for grant under the Plan.

 

    	3

    	 

    

 

5.3.           
Type of Common Stock. Common Stock issued under the Plan in connection with Incentives will be authorized and unissued shares.

 

5.4.           
Limitation on Certain Grants. During any one fiscal year, no person shall receive Incentives under the Plan that could result
in that person receiving, earning or acquiring, subject to the adjustments described in Section 10.6: (a) Stock Options and SARs
for, in the aggregate, more than 20,000,000 shares of Common Stock; or (b) Performance Awards, in the aggregate, for more than
20,000,000 shares of Common Stock or, if payable in cash, with a maximum amount payable exceeding $2,000,000.

 

6.                 
Stock Options. A stock option is a right to purchase shares of Common Stock from the Company. Each stock option granted
by the Committee under this Plan shall be subject to the following terms and conditions:

 

6.1.           
Price. The option price per share shall be determined by the Committee, subject to adjustment under Section 10.6. Notwithstanding
the foregoing sentence, the option price per share shall not be less than the Fair Market Value (as defined in Section 10.15) of
the Common Stock on the Grant Date (as defined in Section 10.16).

  

6.2.           
Number. The number of shares of Common Stock subject to a stock option shall be determined by the Committee, subject to
adjustment as provided in Section 10.6. The number of shares of Common Stock subject to a stock option shall be reduced in the
same proportion that the holder thereof exercises an SAR if any SAR is granted in conjunction with or related to the stock option.
If the number of shares subject to a stock option is reduced pursuant to the preceding sentence, the number of shares subject to
the original grant will continue to count against the limitation on grants under Section 5.4.

 

6.3.           
Duration and Time for Exercise. Subject to earlier termination as provided in Section 10.3, the term of each stock option
shall be determined by the Committee but shall not exceed ten years and one day from the Grant Date. Each stock option shall become
exercisable at such time or times during its term as shall be determined by the Committee at the time of grant. The Committee may
accelerate the exercisability of any stock option. Subject to the first sentence of this paragraph, the Committee may extend the
term of any stock option to the extent provided in Section 10.4.

 

6.4.           
Manner of Exercise. A stock option may be exercised, in whole or in part, by giving written notice to the Company, specifying
the number of shares of Common Stock to be purchased and accompanied by the full purchase price for such shares. The option price
shall be payable (a) in United States dollars upon exercise of the option and may be paid by cash, uncertified or certified check
or bank draft; (b) unless otherwise provided in the option agreement, by delivery of shares of Common Stock in payment of all or
any part of the option price, which shares shall be valued for this purpose at the Fair Market Value on the date such option is
exercised; or (c) unless otherwise provided in the option agreement, by instructing the Company to withhold from the shares of
Common Stock issuable upon exercise of the stock option shares of Common Stock in payment of all or any part of the exercise price
and/or any related withholding tax obligations consistent with Section 10.8, which shares shall be valued for this purpose at the
Fair Market Value or in such other manner as may be authorized from time to time by the Committee. Before the issuance of shares
of Common Stock upon the exercise of a stock option, a participant shall have no rights as a shareholder.

 

6.5.           
Incentive Stock Options. Notwithstanding anything in the Plan to the contrary, the following additional provisions shall
apply to the grant of stock options which are intended to qualify as Incentive Stock Options (as such term is defined in Code Section
422):

 

    	4

    	 

    

 

(a)   
The aggregate Fair Market Value (determined as of the time the option is granted) of the shares of Common Stock with respect to
which Incentive Stock Options are exercisable for the first time by any participant during any calendar year (under all of the
Company’s plans) shall not exceed $100,000. The determination will be made by taking Incentive Stock Options into account
in the order in which they were granted. If such excess only applies to a portion of an Incentive Stock Option, the Committee,
in its discretion, will designate which shares will be treated as shares to be acquired upon exercise of an Incentive Stock Option.

  

(b)  
Any option agreement for an Incentive Stock Option under the Plan shall contain such other provisions as the Committee shall deem
advisable, but shall in all events be consistent with and contain all provisions required in order to qualify the options as Incentive
Stock Options.

 

(c)   
All Incentive Stock Options must be granted within ten years from the earlier of the date on which this Plan was adopted by Board
of Directors or the date this Plan was approved by the shareholders.

 

(d)  
Unless sooner exercised, all Incentive Stock Options shall expire no later than ten years after the Grant Date.

 

(e)   
The option price for Incentive Stock Options shall be not less than the Fair Market Value of the Common Stock subject to the option
on the Grant Date.

 

(f)   
If Incentive Stock Options are granted to any participant who, at the time such option is granted, would own (within the meaning
of Code Section 422) stock possessing more than 10% of the total combined voting power of all classes of stock of the employer
corporation or of its parent or subsidiary corporation, (i) the option price for such Incentive Stock Options shall be not less
than 110% of the Fair Market Value of the Common Stock subject to the option on the Grant Date and (ii) such Incentive Stock Options
shall expire no later than five years after the Grant Date.

 

7.                 
Stock Appreciation Rights. An SAR is a right to receive, without payment to the Company, a number of shares of Common Stock,
the amount of which is determined pursuant to the formula set forth in Section 7.5. An SAR may be granted (a) with respect to any
stock option granted under this Plan, either concurrently with the grant of such stock option or at such later time as determined
by the Committee (as to all or any portion of the shares of Common Stock subject to the stock option), or (b) alone, without reference
to any related stock option. Each SAR granted by the Committee under this Plan shall be subject to the following terms and conditions:

 

7.1.           
Price. The exercise price per share of any SAR granted without reference to a stock option shall be determined by the Committee,
subject to adjustment under Section 10.6. Notwithstanding the foregoing sentence, the exercise price per share shall not be less
than the Fair Market Value of the Common Stock on the Grant Date.

 

7.2.           
Number. Each SAR granted to any participant shall relate to such number of shares of Common Stock as shall be determined
by the Committee, subject to adjustment as provided in Section 10.6. In the case of an SAR granted with respect to a stock option,
the number of shares of Common Stock to which the SAR relates shall be reduced in the same proportion that the holder of the option
exercises the related stock option. If the number of shares subject to an SAR is reduced pursuant to the preceding sentence, the
number of shares subject to the original grant will continue to count against the limitation on grants under Section 5.4.

 

7.3.           
Duration. Subject to earlier termination as provided in Section 10.3, the term of each SAR shall be determined by the Committee
but shall not exceed ten years and one day from the Grant Date. Unless otherwise provided by the Committee, each SAR shall become
exercisable at such time or times, to such extent and upon such conditions as the stock option, if any, to which it relates is
exercisable. The Committee may in its discretion accelerate the exercisability of any SAR. Subject to the first sentence of this
paragraph, the Committee may extend the term of any SAR to the extent provided in Section 10.4.

 

    	5

    	 

    

 

7.4.           
Exercise. An SAR may be exercised, in whole or in part, by giving written notice to the Company, specifying the number of
SARs which the holder wishes to exercise. Upon receipt of such written notice, the Company shall, within 90 days thereafter, deliver
to the exercising holder certificates for the shares of Common Stock or cash or both, as determined by the Committee, to which
the holder is entitled pursuant to Section 7.5.

 

7.5.           
Issuance of Shares Upon Exercise. The number of shares of Common Stock which shall be issuable upon the exercise of an SAR
shall be determined by dividing:

 

(a)   
the number of shares of Common Stock as to which the SAR is exercised multiplied by the amount of the appreciation in such shares
(for this purpose, the “appreciation” shall be the amount by which the Fair Market Value of the shares of Common Stock
subject to the SAR on the exercise date exceeds (1) in the case of an SAR related to a stock option, the purchase price of the
shares of Common Stock under the stock option or (2) in the case of an SAR granted alone, without reference to a related stock
option, an amount which shall be determined by the Committee at the time of grant, subject to adjustment under Section 10.6); by

 

(b)  
the Fair Market Value of a share of Common Stock on the exercise date.

 

No fractional
shares of Common Stock shall be issued upon the exercise of an SAR; instead, the holder of the SAR shall be entitled to receive
a cash adjustment equal to the same fraction of the Fair Market Value of a share of Common Stock on the exercise date or to purchase
the portion necessary to make a whole share at its Fair Market Value on the date of exercise.

 

8.                 
Stock Awards, Restricted Stock and Restricted Stock Units. A stock award consists of the transfer by the Company to a participant
of shares of Common Stock, with or without other payment therefor, as additional compensation for services to the Company. A share
of restricted stock consists of shares of Common Stock which are sold or transferred by the Company to a participant at a price,
if any, determined by the Committee and subject to restrictions on their sale or other transfer by the participant. Restricted
stock units represent the right to receive shares of Common Stock at a future date. The transfer of Common Stock pursuant to stock
awards, ,the transfer or sale of restricted stock and restricted stock units shall be subject to the following terms and conditions:

 

8.1.           
Number of Shares. The number of shares to be transferred or sold by the Company to a participant pursuant to a stock award
or as restricted stock, or the number of shares that may be issued pursuant to a restricted stock unit, shall be determined by
the Committee.

 

8.2.           
Sale Price. The Committee shall determine the price, if any, at which shares of restricted stock shall be sold to a participant,
which may vary from time to time and among participants and which may be below the Fair Market Value of such shares of Common Stock
at the date of sale.

 

8.3.           
Restrictions. All shares of restricted stock transferred or sold by the Company hereunder, and all restricted stock units
granted hereunder, shall be subject to such restrictions as the Committee may determine, including, without limitation any or all
of the following:

 

(a)   
a prohibition against the sale, transfer, pledge or other encumbrance of the shares of restricted stock, or the delivery of shares
pursuant to restricted stock units, such prohibition to lapse at such time or times as the Committee shall determine (whether in
annual or more frequent installments, at the time of the death, disability or retirement of the holder of such shares, or otherwise);

 

(b)  
a requirement that the holder of shares of restricted stock or restricted stock units forfeit, or (in the case of shares sold to
a participant) re-sell back to the Company at his or her cost, all or a part of such shares in the event of termination of his
or her employment, service on the Board of Directors or consulting engagement during any period in which such shares are subject
to restrictions; and

 

(c)   
such other conditions or restrictions as the Committee may deem advisable.

 

    	6

    	 

    

 

8.4.           
Enforcement of Restrictions. In order to enforce the restrictions imposed by the Committee pursuant to Section 8.3, the
participant receiving restricted stock or restricted stock units shall enter into an agreement with the Company setting forth the
conditions of the grant. Shares of restricted stock shall be registered in the name of the participant and deposited, together
with a stock power endorsed in blank, with the Company. Each such certificate shall bear a legend that refers to the Plan and the
restrictions imposed under the applicable agreement. At the Committee’s election, shares of restricted stock may be held
in book entry form subject to the Company’s instructions until any restrictions relating to the restricted stock grant lapse.

 

8.5.           
End of Restrictions. Subject to Section 10.5, at the end of any time period during which the shares of restricted stock
are subject to forfeiture and restrictions on transfer, such shares will be delivered free of all restrictions to the participant
or to the participant’s legal representative, beneficiary or heir. Subject to Section 10.5, upon the lapse or waiver of restrictions
applicable to restricted stock units, or at a later time specified in the agreement governing the grant of restricted stock units,
any shares derived from the restricted stock units shall be issued and delivered to the holder of the restricted stock units.

 

8.6.           
Rights of Holders of Restricted Stock and Restricted Stock Units. Subject to the terms and conditions of the Plan, each
participant receiving restricted stock shall have all the rights of a shareholder with respect to shares of stock during any period
in which such shares are subject to forfeiture and restrictions on transfer, including without limitation, the right to vote such
shares. Any holder of restricted stock units shall not be, and shall not have rights and privileges of, a shareholder with respect
to any shares that may be derived from the restricted stock units unless and until such shares have been issued.

  

8.7.           
Settlement of Restricted Stock Units.  Restricted stock units may be satisfied by delivery of shares of stock,
cash equal to the Fair Market Value of the specified number of shares covered by the restricted stock units, or a combination thereof,
as determined by the Committee at the date of grant or thereafter.

 

8.8.           
Dividend Equivalents. In connection with any award of restricted stock units, the Committee may grant the right to receive
cash, shares of stock or other property equal in value to dividends paid with respect to the number of shares represented by the
restricted stock units (“Dividend Equivalents”). Unless otherwise determined by the Committee at the date of grant,
any Dividend Equivalents that are granted with respect to any award of restricted stock units shall be either (a) paid with respect
to such restricted stock units at the dividend payment date in cash or in shares of unrestricted stock having a Fair Market Value
equal to the amount of such dividends, or (b) deferred with respect to such restricted stock units and the amount or value thereof
automatically deemed reinvested in additional restricted stock units until the time for delivery of shares (if any) pursuant to
the terms of the restricted stock unit award.

 

9.                 
Performance Awards.

 

9.1.           
Performance Conditions. The right of a participant to exercise or receive a grant or settlement of any Incentive, and the
timing thereof, may be subject to such performance conditions as may be specified by the Committee (such an Incentive is referred
to as a “Performance Award”). The Committee may use such business criteria and other measures of performance as it
may deem appropriate in establishing any performance conditions, and may exercise its discretion to reduce the amounts payable
under any Incentive subject to performance conditions, except as limited under Section 9.2 hereof in the case of a Performance
Award intended to qualify under Code Section 162(m). If and to the extent required under Code Section 162(m), any power or authority
relating to a Performance Award intended to qualify under Code Section 162(m), shall be exercised by the Committee as the Committee
and not the Board.

 

9.2.           
Performance Awards Granted to Designated Covered Employees. If and to the extent the Committee determines that a Performance
Award to be granted to a person who is designated by the Committee as likely to be a covered employee within the meaning of Code
Section 162(m) and regulations thereunder (a “Covered Employee”) should qualify as "performance-based compensation"
for purposes of Code Section 162(m), the grant, exercise, and/or settlement of such Performance Award shall be contingent upon
achievement of pre-established performance goals and other terms set forth in this Section 9.2.

  

    	7

    	 

    

 

(a)   
Performance Goals Generally. The performance goals for such Performance Awards shall consist of one or more business criteria
and a targeted level or levels of performance with respect to each of such criteria, as specified by the Committee consistent with
this Section 9.2. Performance goals shall be objective and shall otherwise meet the requirements of Code Section 162(m), including
but not limited to the requirement that the level or levels of performance targeted by the Committee result in the achievement
of performance goals being "substantially uncertain" at the time the Performance Award is granted. The Committee may
determine that such Performance Awards shall be granted, exercised, and/or settled upon achievement of any one performance goal,
or that two or more of the performance goals must be achieved as a condition to grant, exercise, and/or settlement of such Performance
Awards. Performance goals may differ for Performance Awards granted to any one participant or to different participants.

 

(b)  
Business Criteria. One or more of the following business criteria for the Company, on a consolidated basis, and/or specified
subsidiaries or business units of the Company, shall be used exclusively by the Committee in establishing performance goals for
such Performance Awards as are intended to qualify as “performance-based” compensation within the meaning of Section
162(m) of the Code: earnings per share, operating income or profit, net income, gross or net sales, expenses, expenses as a percentage
of net sales, inventory turns, cash flow (including, but not limited to, operating cash flow, free cash flow, cash flow return
on equity, and cash flow return on investment), gross profit, margins, working capital, earnings before interest and tax (EBIT),
earnings before interest, tax, depreciation and amortization (EBITDA), return measures (including, but not limited to, return on
assets, capital, invested capital, equity, sales, or revenue), revenue growth, share price (including, but not limited to, growth
measures and total shareholder return), operating efficiency, productivity ratios, market share, economic value added and safety
(or any of the above criteria as compared to the performance of a group of comparable companies, or any published or special index
that the Committee, in its sole discretion, deems appropriate), or the Committee may select criteria based on the Company’s
share price as compared to various stock market indices. The Committee, in its sole discretion, may modify the performance goals
if it determines that circumstances have changed and modification is required to reflect the original intent of the performance
goals; provided, however, that no such change or modification may be made to the extent it increases the amount of compensation
payable to any participant who is a Covered Employee.

 

(c)   
Performance Period; Timing For Establishing Performance Goals. Achievement of performance goals in respect of such Performance
Awards shall be measured over a performance period of up to ten (10) years, as specified by the Committee. Performance goals shall
be established not later than ninety (90) days after the beginning of any performance period applicable to such Performance Awards,
or at such other date as may be required or permitted for "performance-based compensation" under Code Section 162(m).

  

(d)  
Settlement of Performance Awards; Other Terms. Settlement of such Performance Awards shall be in cash, stock, other Incentives
or other property, in the discretion of the Committee. The Committee may, in its discretion, reduce the amount of a settlement
otherwise to be made in connection with such Performance Awards. The Committee shall specify the circumstances in which such Performance
Awards shall be paid or forfeited in the event of termination of continuous service by the participant before the end of a performance
period or the settlement date of Performance Awards.

 

9.3.           
Written Determinations. All determinations by the Committee as to the establishment of performance goals, the amount of
any Performance Award pool or potential individual Performance Awards, and as to the achievement of performance goals relating
to Performance Awards under Section 9.2(a), shall be made in writing in the case of any Performance Award intended to qualify under
Code Section 162(m). The Committee may not delegate any responsibility relating to such Performance Awards if and to the extent
required to comply with Code Section 162(m).

 

    	8

    	 

    

 

9.4.           
Status of Performance Awards Under Code Section 162(m). It is the intent of the Company that Performance Awards granted
under this Section 9 to persons who are designated by the Committee as likely to be Covered Employees shall, if so designated by
the Committee, constitute "qualified performance-based compensation" within the meaning of Code Section 162(m). Accordingly,
the terms of Sections 9.2, 9.3 and 9.4, including the definitions of Covered Employee and other terms used therein, shall be interpreted
in a manner consistent with Code Section 162(m). Notwithstanding the foregoing, because the Committee cannot determine with certainty
whether a given Participant will be a Covered Employee with respect to a fiscal year that has not yet been completed, the term
Covered Employee as used herein shall mean only a person designated by the Committee, at the time of grant of Performance Awards,
as likely to be a Covered Employee with respect to that fiscal year. If any provision of the Plan or any agreement relating to
such Performance Awards does not comply or is inconsistent with the requirements of Code Section 162(m), such provision shall be
construed or deemed amended to the extent necessary to conform to such requirements.

 

10.             
General.

 

10.1.       
Plan Effective Date and Shareholder Approval; Termination of Plan. The Plan shall become effective on the Effective Date,
subject to subsequent approval within twelve (12) months of its adoption by the Board by shareholders of the Company eligible to
vote in the election of directors, by a vote sufficient to meet the requirements of Code Sections 162(m) (if applicable) and 422,
Rule 16b-3 under the Exchange Act (if applicable), applicable requirements of any stock exchange, if any, and other laws, regulations,
and obligations of the Company applicable to the Plan. Awards may be granted subject to shareholder approval, but may not be exercised
or otherwise settled in the event shareholder approval is not obtained. The Plan shall terminate no later than ten (10) years from
the date of the later of (x) the Effective Date and (y) the date an increase in the number of shares reserved for issuance under
the Plan is approved by the Board (so long as such increase is also approved by the shareholders).

 

10.2.       
Duration. The Plan shall remain in effect until all Incentives granted under the Plan have either been satisfied by the
issuance of shares of Common Stock or the payment of cash or been terminated under the terms of the Plan and all restrictions imposed
on shares of Common Stock in connection with their issuance under the Plan have lapsed. No Incentives may be granted under the
Plan after the tenth anniversary of the Effective Date of the Plan.

 

10.3.       
Non-transferability of Incentives. No stock option, SAR, restricted stock or stock award may be transferred, pledged or
assigned by the holder thereof (except, in the event of the holder’s death, by will or the laws of descent and distribution
to the limited extent provided in the Plan or the Incentive, or pursuant to a qualified domestic relations order as defined by
the Code or Title I of the Employee Retirement Income Security Act, or the rules thereunder), and the Company shall not be required
to recognize any attempted assignment of such rights by any participant. Notwithstanding the preceding sentence, stock options
(other than stock options intended to qualify as Incentive Stock Options pursuant to Section 6.5) may be transferred by the holder
thereof to the holder’s spouse, children, grandchildren or parents (collectively, the “Family Members”), to trusts
for the benefit of Family Members, to partnerships or limited liability companies in which Family Members are the only partners
or shareholders, or to entities exempt from federal income taxation pursuant to Code Section 501(c)(3). During a participant’s
lifetime, a stock option may be exercised only by him or her, by his or her guardian or legal representative or by the transferees
permitted by this Section 10.3.

 

10.4.       
Effect of Termination or Death. If a participant ceases to be an employee of or consultant to the Company for any reason,
including death or disability, any Incentives may be exercised or shall expire at such times as may be set forth in the agreement,
if any, applicable to the Incentive, or otherwise as determined by the Committee; provided, however, the term of an Incentive may
not be extended beyond the term originally prescribed when the Incentive was granted, unless the Incentive satisfies (or is amended
to satisfy) the requirements of Code Section 409A, including the rules and regulations promulgated thereunder (together, “Code
Section 409A”); and provided further that the term of an Incentive may not be extended beyond the maximum term permitted
under this Plan.

 

    	9

    	 

    

 

10.5.       
Restrictions under Securities Laws. Notwithstanding anything in this Plan to the contrary: (a) the Company may, if it shall
determine it necessary or desirable for any reason, at the time of award of any Incentive or the issuance of any shares of Common
Stock pursuant to any Incentive, require the recipient of the Incentive, as a condition to the receipt thereof or to the receipt
of shares of Common Stock issued pursuant thereto, to deliver to the Company a written representation of present intention to acquire
the Incentive or the shares of Common Stock issued pursuant thereto for his or her own account for investment and not for distribution;
and (b) if at any time the Company further determines, in its sole discretion, that the listing, registration or qualification
(or any updating of any such document) of any Incentive or the shares of Common Stock issuable pursuant thereto is necessary on
any securities exchange or under any federal or state securities or blue sky law, or that the consent or approval of any governmental
regulatory body is necessary or desirable as a condition of, or in connection with the award of any Incentive, the issuance of
shares of Common Stock pursuant thereto, or the removal of any restrictions imposed on such shares, such Incentive shall not be
awarded or such shares of Common Stock shall not be issued or such restrictions shall not be removed, as the case may be, in whole
or in part, unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of
any conditions not acceptable to the Company.

 

10.6.       
Adjustment. In the event of any recapitalization, stock dividend, stock split, combination of shares or other change in
the Common Stock, the number of shares of Common Stock then subject to the Plan, including shares subject to outstanding Incentives,
and the other numbers of shares of Common Stock provided in the Plan, shall be adjusted in proportion to the change in outstanding
shares of Common Stock. In the event of any such adjustments, the purchase price of any option, the performance objectives of any
Incentive, and the shares of Common Stock issuable pursuant to any Incentive shall be adjusted as and to the extent appropriate,
in the discretion of the Committee, to provide participants with the same relative rights before and after such adjustment.

 

10.7.       
Incentive Plans and Agreements. Except in the case of stock awards, the terms of each Incentive shall be stated in a plan
or agreement approved by the Committee. The Committee may also determine to enter into agreements with holders of options to reclassify
or convert certain outstanding options, within the terms of the Plan, as Incentive Stock Options or as non-statutory stock options
and in order to eliminate SARs with respect to all or part of such options and any other previously issued options. The Committee
shall communicate the key terms of each award to the participant promptly after the Committee approves the grant of such award.

 

10.8.       
Withholding.

 

(a)   
The Company shall have the right to withhold from any payments made under the Plan or to collect as a condition of payment, any
taxes required by law to be withheld. If so permitted by the Committee at the time of the award of any Incentive or at a later
time, at any time when a participant is required to pay to the Company an amount required to be withheld under applicable income
tax laws in connection with a distribution of Common Stock or upon exercise of an option or SAR or upon vesting of restricted stock,
the participant may satisfy this obligation in whole or in part by electing (the “Election”) to have the Company withhold,
from the distribution or from such shares of restricted stock, shares of Common Stock having a value up to the minimum amount of
withholding taxes required to be collected on the transaction. The value of the shares to be withheld shall be based on the Fair
Market Value of the Common Stock on the date that the amount of tax to be withheld shall be determined (“Tax Date”).

 

(b)  
Each Election must be made before the Tax Date. The Committee may disapprove of any Election, may suspend or terminate the right
to make Elections, or may provide with respect to any Incentive that the right to make Elections shall not apply to such Incentive.
An Election is irrevocable.

 

10.9.       
No Continued Employment, Engagement or Right to Corporate Assets. No participant under the Plan shall have any right, because
of his or her participation, to continue in the employ of the Company for any period of time or to any right to continue his or
her present or any other rate of compensation. Nothing contained in the Plan shall be construed as giving an employee, a consultant,
such persons’ beneficiaries or any other person any equity or interests of any kind in the assets of the Company or creating
a trust of any kind or a fiduciary relationship of any kind between the Company and any such person.

 

    	10

    	 

    

 

10.10.   
Payments Under Incentives. Payment of cash or distribution of any shares of Common Stock to which a participant is entitled
under any Incentive shall be made as provided in the Incentive. Except as permitted under Section 10.17, payments and distributions
may not be deferred under any Incentive unless the deferral complies with the requirements of Code Section 409A.

 

10.11.   
Amendment of the Plan. The Board of Directors may amend or discontinue the Plan at any time. However, no such amendment
or discontinuance shall adversely change or impair, without the consent of the recipient, an Incentive previously granted. Further,
no such amendment shall, without approval of the shareholders of the Company, (a) increase the maximum number of shares of Common
Stock which may be issued to all participants under the Plan, (b) change or expand the types of Incentives that may be granted
under the Plan, (c) change the class of persons eligible to receive Incentives under the Plan, or (d) materially increase the benefits
accruing to participants under the Plan.

 

10.12.   
Amendment of Agreements for Incentives; No Repricing. Except as otherwise provided in this Section 10.12 or Section 10.17,
the terms of an existing Incentive may be amended by agreement between the Committee and the participant. Notwithstanding the foregoing
sentence, in the case of a stock option or SAR, no such amendment shall (a) without shareholder approval, lower the exercise price
of a previously granted stock option or SAR, cancel a stock option or SAR when the exercise price per share exceeds the Fair Market
Value of the underlying shares in exchange for another Incentive or cash, or take any other action with respect to a stock option
that may be treated as a repricing under the federal securities laws or generally accepted accounting principles; or (b) extend
the term of the Incentive, except as provided in Sections 10.4 and 10.17.

  

10.13.   
Vesting Upon Change In Control. Upon the occurrence of an event satisfying the definition of “Change in Control”
with respect to a particular Incentive, unless otherwise provided in the agreement for the Incentive, such Incentive shall become
vested and all restrictions shall lapse. The Committee may, in its discretion, include such further provisions and limitations
in any agreement for an Incentive as it may deem desirable. For purposes of this Section 10.13, “Change in Control”
means the occurrence of any one or more of the following:

 

(a)   
a merger, consolidation, statutory exchange or reorganization approved by the Company’s shareholders, unless securities representing
more than fifty percent (50%) of the total combined voting power of the outstanding voting securities of the successor corporation
are immediately thereafter beneficially owned directly or indirectly and in substantially the same proportion, by the persons who
beneficially owned the Company’s outstanding voting securities immediately prior to such transaction;

 

(b)  
any transaction or series of related transactions pursuant to which any person or any group of persons comprising a “group”
within the meaning of Rule 13d-5(b)(1) under the Securities Exchange Act of 1934, as amended (other than the Company or a person
that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under
common control with, the Company) becomes directly or indirectly the beneficial owner (within the meaning of Rule 13d-3 of the
Securities Exchange Act of 1934, as amended) of securities possessing (or convertible into or exercisable for securities possessing)
thirty percent (30%) or more of the total combined voting power of the securities (determined by the power to vote with respect
to the elections of Board members) outstanding immediately after the consummation of such transaction or series of related transactions,
whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or
more of the Company’s shareholders;

 

(c)   
there is consummated a sale, lease, exclusive license, or other disposition of all or substantially all of the consolidated assets
of the Company and its subsidiaries, other than a sale, lease, license, or other disposition of all or substantially all of the
consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%) of the combined voting power
of the voting securities of which are owned by shareholders of the Company in substantially the same proportions as their ownership
of the Company immediately prior to such sale, lease, license, or other disposition; or

 

    	11

    	 

    

 

(d)  
individuals who, on the Effective Date, are Directors (the “Incumbent Board”) cease for any reason to constitute at
least a majority of the Directors; provided, however, that if the appointment or election (or nomination for election) of any new
Director was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member
shall, for purposes of this Plan, be considered as a member of the Incumbent Board.

  

Notwithstanding the foregoing
or any other provision of this Plan, (i) the definition of Change in Control (or any analogous term) in an individual written agreement
between the Company and the Participant shall supersede the foregoing definition with respect to Incentives subject to such agreement
(it being understood, however, that if no definition of Change in Control or any analogous term is set forth in such an individual
written agreement, the foregoing definition shall apply); (ii) for clarification, a “Change in Control” shall not be
deemed to have occurred for purposes of the foregoing clause (b) as the result of the acquisition of additional securities by Dr.
Samuel Herschkowitz, Joshua Kornberg or their affiliates; and (iii) a “Change in Control” shall not be deemed to have
occurred for purposes of the foregoing clause (b) solely as the result of a repurchase or other acquisition of securities by Company
which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities
beneficially owned by any person to thirty percent (30%) or more of the combined voting power of all of the then outstanding Voting
Securities; provided, however, that if any person referred to in this clause (iii) shall thereafter become the beneficial owner
of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or
as a result of an acquisition of securities directly from Company) and immediately thereafter beneficially owns thirty percent
(30%) or more of the combined voting power of all of the then outstanding Voting Securities, then a “Change in Control”
shall be deemed to have occurred for purposes of the foregoing clause (b).

 

10.14.   
Sale, Merger, Exchange or Liquidation. Unless otherwise provided in the agreement for an Incentive, in the event of an acquisition
of the Company through the sale of substantially all of the Company’s assets or through a merger, exchange, reorganization
or liquidation of the Company or a similar event as determined by the Committee (collectively a “transaction”), the
Committee shall be authorized, in its sole discretion, to take any and all action it deems equitable under the circumstances, including
but not limited to any one or more of the following:

 

(a)   
providing that the Plan and all Incentives shall terminate and the holders of (i) all outstanding vested options shall receive,
in lieu of any shares of Common Stock they would be entitled to receive under such options, such stock, securities or assets, including
cash, as would have been paid to such participants if their options had been exercised and such participant had received Common
Stock immediately before such transaction (with appropriate adjustment for the exercise price, if any), (ii) SARs that entitle
the participant to receive Common Stock shall receive, in lieu of any shares of Common Stock each participant was entitled to receive
as of the date of the transaction pursuant to the terms of such Incentive, if any, such stock, securities or assets, including
cash, as would have been paid to such participant if such Common Stock had been issued to and held by the participant immediately
before such transaction, and (iii) any Incentive under this Agreement which does not entitle the participant to receive Common
Stock shall be equitably treated as determined by the Committee.

 

(b)  
providing that participants holding outstanding vested Common Stock based Incentives shall receive, with respect to each share
of Common Stock issuable pursuant to such Incentives as of the effective date of any such transaction, at the determination of
the Committee, cash, securities or other property, or any combination thereof, in an amount equal to the excess, if any, of the
Fair Market Value of such Common Stock on a date within ten days before the effective date of such transaction over the option
price or other amount owed by a participant, if any, and that such Incentives shall be cancelled, including the cancellation without
consideration of all options that have an exercise price below the per share value of the consideration received by the Company
in the transaction.

 

    	12

    	 

    

 

(c)   
providing that the Plan (or replacement plan) shall continue with respect to Incentives not cancelled or terminated as of the effective
date of such transaction and provide to participants holding such Incentives the right to earn their respective Incentives on a
substantially equivalent basis (taking into account the transaction and the number of shares or other equity issued by such successor
entity) with respect to the equity of the entity succeeding the Company by reason of such transaction.

 

(d)  
to the extent that the vesting of any Incentives is not accelerated pursuant to Section 10.13, providing that all unvested, unearned
or restricted Incentives, including but not limited to restricted stock for which restrictions have not lapsed as of the effective
date of such transaction, shall be void and deemed terminated, or, in the alternative, for the acceleration or waiver of any vesting,
earning or restrictions on any Incentive.

 

The Board
of Directors may restrict the rights of participants or the applicability of this Section 10.14 to the extent necessary to comply
with Section 16(b) of the 1934 Act, the Code or any other applicable law or regulation. The grant of an Incentive award pursuant
to the Plan shall not limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations
or changes of its capital or business structure or to merge, exchange or consolidate or to dissolve, liquidate, sell or transfer
all or any part of its business or assets.

 

10.15.   
Definition of Fair Market Value. For purposes of this Plan, the “Fair Market Value” of a share of Common Stock
at a specified date shall, unless otherwise expressly provided in this Plan, be the amount which the Committee determines in good
faith to be 100% of the fair market value of such a share as of the date in question. Notwithstanding the foregoing:

 

(a)   
If such shares are listed on a U.S. securities exchange, then Fair Market Value shall be determined by reference to the last sale
price of a share of Common Stock on such U.S. securities exchange on the applicable date. If such U.S. securities exchange is closed
for trading on such date, or if the Common Stock does not trade on such date, then the last sale price used shall be the one on
the date the Common Stock last traded on such U.S. securities exchange.

 

(b)  
If such shares are publicly traded but are not listed on a U.S. securities exchange, then Fair Market Value shall be determined
by reference to the trading price of a share of Common Stock on such date (or, if the applicable market is closed on such date,
the last date on which the Common Stock was publicly traded), by a method consistently applied by the Committee.

 

(c)   
If such shares are not publicly traded, then the Committee’s determination will be based upon a good faith valuation of the
Company’s Common Stock as of such date, which shall be based upon such factors as the Committee deems appropriate. The valuation
shall be accomplished in a manner that complies with Code Section 409A and shall be consistently applied to Incentives under the
Plan.

 

10.16.   
Definition of Grant Date. For purposes of this Plan, the “Grant Date” of an Incentive shall be the date on which
the Committee approved the award or, if later, the date established by the Committee as the date of grant of the Incentive.

 

10.17.    Compliance
with Code Section 409A.

 

(a)   
Except to the extent such acceleration or deferral is permitted by the requirements of Code Section 409A, neither the Committee
nor a participant may accelerate or defer the time or schedule of any payment of, or the amount scheduled to be paid under, an
Incentive that constitutes Deferred Compensation (as defined in paragraph(d) below); provided, however, that payment shall be permitted
if it is in accordance with a “specified time” or “fixed schedule” or on account of “separation from
service,” “disability,” death, “change in control” or “ unforeseeable emergency” (as
those terms are defined under Code Section 409A) that is specified in the agreement evidencing the Incentive.

 

    	13

    	 

    

 

(b)  
Notwithstanding anything in this Plan, unless the agreement evidencing the Incentive specifically provides otherwise, if a participant
is treated as a Specified Employee (as defined in paragraph (d) and as determined under Code Section 409A by the Committee in good
faith) as of the date of his or her “separation from service” as defined for purposes of Code Section 409A, the Company
may not make payment to the participant of any Incentive that constitutes Deferred Compensation, earlier than 6 months following
the participant’s separation from service (or if earlier, upon the Specified Employee’s death), except as permitted
under Code Section 409A. Any payments that otherwise would be payable to the Specified Employee during the foregoing 6-month period
will be accumulated and payment delayed until the first date after the 6-month period. The Committee may specify in the Incentive
agreement, that the amount of the Deferred Compensation delayed under this paragraph shall accumulate interest, earnings or Dividend
Equivalents (as applicable) during the period of such delay.

 

(c)   
The Committee may, however, reform any provision in an Incentive that is intended to comply with (or be exempt from) Code Section
409A, to maintain to the maximum extent practicable the original intent of the applicable provision without violating the provisions
of Code Section 409A.

 

(d)  
For purposes of this Section 10.17, "Deferred Compensation" means any Incentive under this Plan that provides for the
“deferral of compensation” under a “nonqualified deferred compensation plan” (as those terms are defined
under Code Section 409A) and that would be subject to the taxes specified in Code Section 409A(a)(1) if and to the extent that
the Plan and the agreement evidencing the Incentive do not meet or are not operated in compliance with the requirements of paragraphs
(a)(2), (a)(3) and (a)(4) of Code Section 409A . Deferred Compensation shall not include any amount that is otherwise exempt from
the requirements of Code Section 409A. A “Specified Employee” means a Participant who is a “key employee”
as described in Code Section 416 (i) (disregarding paragraph (5) thereof) at any time during the Company’s fiscal year ending
on January 31, or such other “identification date” that applies consistently for all plans of the Company that provide
“deferred compensation” that is subject to the requirements of Code Section 409A. Each participant will be identified
as a Specified Employee in accordance with Code Section 409A, including with respect to the merger of the Company with any other
company or any spin-off or similar transaction, and such identification shall apply for the 12-month period commencing on the first
day of the fourth month following the identification date. Notwithstanding the foregoing, no participant shall be a Specified Employee
unless the stock of the Company (or other member of a “controlled group of corporations” as determined under Code Section
1563) is publicly traded on an established securities market (or otherwise) as of the date of the participant’s “separation
from service” as defined in Code Section 409A.

 

10.18.   
Prior Plan. Notwithstanding the adoption of this Plan by the Board of Directors and its approval by the shareholders, the
Company’s 2008 Equity Incentive Plan, as it has been amended from time to time (the “Prior Plan”), shall remain
in effect, and all grants and awards made under the Prior Plan shall be governed by the terms of the Prior Plan. From and after
the Effective Date, no further grants and awards shall be made under the Prior Plan.

 

Approved by the Board
of Directors on August 13, 2012.

 

Approved by the shareholders
on September 20, 2012.

 

Amendment increasing
share reserve in Section 5.1 from 20,000,000 to 50,000,000 and increasing share limits in Section 5.4 approved by the Board of
Directors on April 1, 2013 and by the shareholders on April 15, 2013.

 

Amendment increasing
share reserve in Section 5.1 from 50,000,000 to 100,000,000 approved by the Board of Directors on August 1, 2013 and by the shareholders
on September 10, 2013. 

 

    	14EXHIBIT 10.7

 

CONFIDENTIAL

 

Execution Copy

 

AMENDED AND RESTATED LICENSE AGREEMENT

 

BETWEEN

 

IPSEN PHARMA SAS

 

AND

 

RHYTHM PHARMACEUTICALS, INC.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

CONFIDENTIAL

 

	
ARTICLE 1
    	
INTERPRETATION   — DEFINITIONS
    	
2
    
	
 
    	
 
    	
 
    
	
ARTICLE 2
    	
GRANT   OF RIGHTS
    	
12
    
	
 
    	
 
    	
 
    
	
ARTICLE 3
    	
MILESTONE   PAYMENTS; PAYMENT OF SHARE OF SUBLICENSING REVENUES
    	
18
    
	
 
    	
 
    	
 
    
	
ARTICLE 4
    	
PAYMENTS   BASED ON SALES OF LICENSED PRODUCT
    	
21
    
	
 
    	
 
    	
 
    
	
ARTICLE 5
    	
PAYMENT,   REPORTING, AUDITING
    	
23
    
	
 
    	
 
    	
 
    
	
ARTICLE 6
    	
DEVELOPMENT
    	
25
    
	
 
    	
 
    	
 
    
	
ARTICLE 7
    	
REGULATORY   MATTERS AND SAFETY
    	
27
    
	
 
    	
 
    	
 
    
	
ARTICLE 8
    	
MANUFACTURE   AND SUPPLY
    	
27
    
	
 
    	
 
    	
 
    
	
ARTICLE 9
    	
COMMERCIALIZATION
    	
28
    
	
 
    	
 
    	
 
    
	
ARTICLE 10
    	
INTELLECTUAL   PROPERTY
    	
29
    
	
 
    	
 
    	
 
    
	
ARTICLE 11
    	
CONFIDENTIAL   INFORMATION
    	
36
    
	
 
    	
 
    	
 
    
	
ARTICLE 12
    	
PUBLICATION   AND PRESS RELEASE
    	
38
    
	
 
    	
 
    	
 
    
	
ARTICLE 13
    	
REPRESENTATIONS,   WARRANTIES AND COVENANTS
    	
39
    
	
 
    	
 
    	
 
    
	
ARTICLE 14
    	
TERM   AND TERMINATION
    	
43
    
	
 
    	
 
    	
 
    
	
ARTICLE 15
    	
INDEMNIFICATION
    	
47
    
	
 
    	
 
    	
 
    
	
ARTICLE 16
    	
DISPUTE   RESOLUTION AND GOVERNING LAW
    	
48
    
	
 
    	
 
    	
 
    
	
ARTICLE 17
    	
MISCELLANEOUS
    	
49
    
	
 
    	
 
    	
 
    
	
APPENDIX A — IPSEN GHRELIN PATENT RIGHTS AS OF   JANUARY 30, 2013
    	
55
    
	
 
    	
 
    	
 
    
	
APPENDIX B-IPSEN ONGOING PRE-CLINICAL STUDIES
    	
56
    
	
 
    	
 
    	
 
    
	
APPENDIX C — INITIAL DEVELOPMENT PLAN
    	
57
    

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

i

 

CONFIDENTIAL

 

LICENSE AGREEMENT

 

This Amended and Restated License Agreement (this “Agreement”) is entered into on March 21, 2013 by and between, on the one hand, IPSEN PHARMA S.A.S., a French corporation, with its principal office at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France, on behalf of itself and its Affiliates (collectively, “Ipsen”), and, on the other hand, RHYTHM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware, U.S.A., with its principal office at 855 Boylston Street, 11th Floor, Boston MA 02116, on behalf of itself and its Affiliates (collectively, “Licensee”),  and is effective as of the Effective Date (as defined below).

 

Recitals

 

1.             The Parties are parties to that certain License Agreement, dated as of February 26, 2010 (the “Prior Agreement”).

 

2.             The Licensee is undertaking a reorganization as a result of which its MC4 program is being contributed to a new corporation, which new corporation and the Licensee will have the same parent company (“Rhythm Holding Company, LLC”).  Such new corporation is simultaneously with the execution and delivery of this Agreement entering into a License Agreement relating to the MC4 program with Licensor.

 

3.             As a result of the reorganization described above, the Parties wish to amend and restate the Prior Agreement in its entirety to narrow the rights licensed hereunder to those rights related to the Ghrelin program only as the MC4 program will be covered by a separate license.

 

4.             As a further result of the reorganization described above, simultaneously with the execution and delivery of this Agreement, Licensor and Rhythm Holding Company, LLC will enter into an agreement whereby Licensor will grant to Rhythm Holding Company, LLC the right to cause Licensor to license to any wholly-owned subsidiaries of Rhythm Holding Company, LLC all rights related to the GIP Program and any Additional Ipsen Metabolic  Compounds.

 

5.             Ipsen has discovered and developed certain proprietary compounds that [          ]*.  Ipsen also has [        ]*.

 

6.             Licensee has interest in exclusively licensing the Ipsen Patent Rights (as defined below) and having access to [          ]* thereunder, to pursue a worldwide development program, and thereafter, to commercialize the resulting products.

 

7.             The Parties have prepared this Agreement to govern the development and commercialization of products resulting from this Agreement.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

1

 

CONFIDENTIAL

 

Now, Therefore, in consideration of the premises and the mutual covenants and agreements contained in this Agreement, the Parties, intending to be legally bound, do hereby agree as follows:

 

ARTICLE 1  INTERPRETATION — DEFINITIONS

 

1.1          In this Agreement, unless the context otherwise requires, all references to a particular Article, Section, or Appendix, shall be a reference to that Article, Section or Appendix, in or to this Agreement, as it may be amended from time to time pursuant to this Agreement.

 

1.1.1       Headings are inserted for convenience only and shall not affect the meaning or interpretation of any provision of this Agreement.

 

1.1.2       This Agreement incorporates all Appendices as a part of this Agreement by reference.

 

1.1.3       The term “including” (or any variation thereof such as “include”) shall be without limitation to the generality of the preceding words.

 

1.1.4       Unless the contrary intention appears, words in the singular shall include the plural and vice versa.

 

1.1.5       Unless the contrary intention appears, words denoting persons shall include any individual, partnership, company, corporation, joint venture, trust, association, organization or other entity.

 

1.1.6       Reference to any statute or regulation includes any modification or re-enactment of that statute or regulation.

 

The following capitalized terms, whether used in the singular or the plural, shall have the following meanings as used in this Agreement unless otherwise specifically indicated:

 

1.2          Accounting Period shall mean each [          ]* commencing respectively on [          ]*, each being the first day of an Accounting Period, and finishing respectively on [             ]*, each being the last day of an Accounting Period.

 

1.3          Affiliate shall mean (a) an entity which owns, directly or indirectly, a controlling interest in a Party, by stock ownership or otherwise, (b) any entity in which a Party owns a controlling interest, by stock ownership or otherwise; or (c) any entity, under direct or indirect common control with a Party.  For purposes of this paragraph, “controlling interest” and “control” mean ownership of fifty percent (50%) or more of the voting stock permitted to vote for the election of the board of directors or any other arrangement resulting in control or the right to control the management and the affairs of the Party.  Notwithstanding anything express or implied in the foregoing provisions of this definition, none of (x) the stockholders of Licensee or any entities affiliated with any

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

2

 

CONFIDENTIAL

 

of such stockholders, including, without limitation, other portfolio companies of any of such stockholders or (y) Ipsen or any Affiliate of Ipsen shall be deemed or treated as an Affiliate of Licensee for any purposes of this Agreement.

 

1.4          Agreement shall have the meaning set forth in preamble to this Agreement.

 

1.5          Arbitration Request shall have the meaning set forth in Section 16.3.

 

1.6          Breaching Party shall have the meaning set forth in Section 14.2.

 

1.7          Bundled Product shall mean Licensed Product(s) sold to a third party with one or more other products or services in circumstances where either (i) the price of the Licensed Product(s) is not shown separately on the invoice or (ii) the Licensed Product(s) (or a portion of the units of Licensed Product(s)) are detailed on a separate invoice where the price is shown as nil (free of charge) for the Licensed Product(s) (or for those units of the Licensed Product(s)). Licensed Product supplied with a delivery device (and not otherwise supplied together with, or bundled or combined with, any other product or service) shall not be considered a Bundled Product.

 

1.8          Change-of-Control shall have the meaning ascribed to it in Section 2.10.2.

 

1.9          Clinical Supply Agreements shall have the meaning set forth in Section 8.1.

 

1.10        Competing Product shall mean any [          ]*; provided, however, that a Licensed Product shall not be deemed or treated as a Competing Product for purposes of this Agreement.

 

1.11        Confidential Information shall have the meaning set forth in Section 11.1.

 

1.12        Contractor shall mean any third party with whom Licensee enters into an agreement pursuant to which Licensee grants to such third party the right to perform any services for, and on behalf of, Licensee with respect to any Licensed Product in any country of the Territory, including, without limitation, contract research, contract manufacturing or contract sales or commercialization activities.  Notwithstanding the foregoing, the term “Contractor” shall in no event include (i) any Affiliate of Licensee, (ii) any Sublicensee and (iii) any such third party with whom Licensee enters into an agreement if the relationship established between Licensee and such third party pursuant to such agreement is for such third party to be a wholesale distributor of Licensed Product in any country of the Territory.

 

1.13        Control or Controlled shall mean, with respect to any intellectual property right or other intangible property, the possession (whether by license from a third party or ownership, or by control over an Affiliate having possession by license

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

3

 

CONFIDENTIAL

 

from a third party or ownership) by a Party of the ability to grant to the other Party access, ownership and/or a license or sublicense to such intellectual property right or other intangible property without violating the terms of any agreement with any third party.

 

1.14        Cover (as an adjective or as a verb including conjugations and variations such as “Covered,” “Coverage” or “Covering”) shall mean that the developing, making, using, offering for sale, promoting, selling or importing of a given compound, formulation or product would infringe a Valid Claim of an issued patent in the absence of a license under such Valid Claim. The determination of whether a compound, formulation or product is Covered by a particular Valid Claim shall be made on a country-by-country basis.

 

1.15        Delay shall have the meaning set forth in Section 17.5.

 

1.16        Development shall mean the pre-clinical studies, Phase I, II & III Clinical Trials, filing of NDAs, and other activities, including pharmaceutical and manufacturing development as well as regulatory work, necessary to obtain Regulatory Approval of a Licensed Product.

 

1.17        Development Plan shall mean any version and variations of a document prepared for the Development of each Licensed Product in the Territory, that outlines the Development activities including regulatory strategies, to be performed by Licensee under this Agreement. Such a document shall contain targeted timelines of the Development phases and clinical endpoints.

 

1.18        Discloser shall have the meaning set forth in Section 11.1.

 

1.19        Effective Date shall mean, February 26, 2010.

 

1.20        EMEA shall mean the European Medicines Agency or any successor agency.

 

1.21        FDA shall mean the United States of America Food and Drug Administration or any successor agency.

 

1.22        First Commercial Sale shall mean, in each country of the Territory, each first invoiced sale by Licensee, Affiliate or Sub-Licensee to a third party of Licensed Product in the country after obtaining Regulatory Approval in such country.

 

1.23        FTE shall mean a period equivalent to the number of hours that an employee in the full time employment of either Party would be obliged to spend at work in any twelve (12) month period of continuous employment.

 

1.24        Gross Sales shall mean the gross amount invoiced by Licensee, its Affiliates or Sublicensees for sales of a Licensed Product to third parties in the Territory. For purposes of clarification, [          ]* shall not be considered as Gross

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

4

 

CONFIDENTIAL

 

Sales.  Notwithstanding the foregoing provisions of this definition, sales of Licensed Product [          ]* shall not give rise to any Gross Sales for purposes of this Agreement.

 

1.25        Health Agency shall mean a governmental or official body in a given country of the Territory, including FDA and EMEA, as well as any national or international or local regulatory agency, department, bureau or other governmental entity, which reviews, validates and/or delivers Regulatory Approvals.

 

1.26        Indemnified Party shall have the meaning set forth in Section 15.3.

 

1.27        Indemnified Person shall have the meaning set forth in Section 15.3.

 

1.28        Infringe (as a noun, adjective or verb including conjugations and variations such as “Infringed,” “Infringes”, “Infringing” and “Infringement”) shall mean infringement, misappropriation, unauthorized use, misuse or other violation of the Patent Rights, know-how, inventions, trade secrets or other intellectual property (except trademarks) of any person or entity, whether such person or entity owns such Patent Rights, Know-How, inventions, trade secrets or other intellectual property (except trademarks) or otherwise has the valid right of use thereof, including, without limitation, pursuant to a license.

 

1.29        Initial Development Plan shall mean the Development Plan attached to this Agreement as Appendix C.

 

1.30        Invention shall mean any invention, whether or not patentable, made as a result of the research or Development activities of a Party or the Parties pursuant to this Agreement. An “Invention” may be made by employees of Ipsen solely or jointly with a third party (an “Ipsen Invention”), by employees of Licensee solely or jointly with a third party (a “Licensee Invention”), or jointly by employees of Ipsen and Licensee with or without a third party (a “Joint Invention”), in each instance as determined by U.S. laws of inventorship.

 

1.31        Ipsen shall have the meaning set forth in the preamble to this Agreement.

 

1.32        Ipsen Future Know-How shall mean all Know-How that (A) Ipsen or any of its Affiliates owns or Controls at any time after the Effective Date (and not on or prior to the Effective Date) and during the Term and (B) either (i) is reasonably necessary to research, develop, manufacture, market, promote, use, sell, import or export any Licensed Product or any Unlicensed Product or (ii) is used or practiced by Ipsen, its Affiliates, sublicensees or contractors in connection with the research, Development, manufacture, marketing, promotion, use, sale, import or export of any Competing Product.  Notwithstanding the foregoing provisions of this definition, the term “Ipsen Future Know-How” shall not include Joint Know-How, Ipsen Know-How, Ipsen New Formulation Know-How.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

5

 

CONFIDENTIAL

 

1.33        Ipsen Future Patent Rights shall mean all Patent Rights that (A) Ipsen or any of its Affiliates owns or Controls at any time after the Effective Date (and not on or prior to the Effective Date) and during the Term and (B) claim any invention included within Ipsen Future Know-How.  Notwithstanding the foregoing provisions of this definition, the term “Ipsen Future Patent Rights” shall not include Joint Patent Rights, Ipsen Patent Rights or Ipsen New Formulation Patent Rights.

 

1.34        Ipsen Future Technology shall mean all Ipsen Future Know-How and Ipsen Future Patent Rights.

 

1.35        Ipsen Ghrelin Compound shall mean a [          ]*.

 

1.36        Ipsen Ghrelin Patent Rights shall mean (i) all Patent Rights that are listed in Appendix A of this Agreement and (ii) any and all substitutions, extensions or supplementary protection certificates, reissues, re-examinations, renewals, divisions, continuations, continuations-in-part and foreign counterparts with respect to such Patent Rights.

 

1.37        Ipsen Ghrelin Product shall mean any [          ]*.

 

1.38        Ipsen Ghrelin Program shall mean the [          ]* program conducted by or on behalf of Ipsen or any of its Affiliates (alone or together with one or more Affiliates, partners, contractors or sublicensees) at any time on or prior to the Effective Date for purposes of [          ]*.

 

1.39        Ipsen Ghrelin Program Invention shall mean any invention or Know-How that (A) has been conceived, created, used or practiced in the course of carrying out the Ipsen Ghrelin Program or has been conceived, created or reduced to practice for the purpose of being used in the conduct of the Ipsen Ghrelin Program or (B) consists of the composition of matter, formulation, any method of use or any method of manufacture of any Ipsen Ghrelin Compound.

 

1.40        Ipsen Indemnitees shall have the meaning set forth in Section 15.2.

 

1.41        Ipsen Joint Technology Rights shall mean all of Ipsen’s right, title and interest in the Joint Patent Rights and the Joint Know-How.

 

1.42        Ipsen Know-How shall mean, collectively, (A) all Know-How that Ipsen or any of its Affiliates owns or Controls as of the Effective Date and is necessary or useful to the research, Development, manufacture, marketing, promotion, use, sale, import or export of any Licensed Product, including, without limitation, all data and information regarding the safety and efficacy of any Licensed Product, (B) all Know-How, whether or not patentable, conceived, made, generated or developed by Ipsen or any of its Affiliates as a result of the research or Development activities of Ipsen or any of its Affiliates pursuant to this Agreement, including, without limitation, all Ipsen

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

6

 

CONFIDENTIAL

 

Inventions. The term “Ipsen Know-How” shall not include Joint Know-How or Ipsen New Formulation Know-How.

 

1.43        Ipsen Licensed Know-How shall mean, collectively, (i) the Ipsen Know-How, (ii) the Ipsen Future Know-How and (iii) Ipsen’s right, title and interest in Joint Know-How.

 

1.44        Ipsen Licensed Patent Rights shall mean, collectively, (i) the Ipsen Patent Rights, (ii) the Ipsen [          ]* Patent Rights (if and to the extent not included within the Ipsen Patent Rights), (iii) the Ipsen Future Patent Rights and (iv) Ipsen’s right, title and interest in the Joint Patent Rights.

 

1.45        Ipsen Licensed Technology shall mean all Ipsen Licensed Know-How and Ipsen Licensed Patent Rights.

 

1.46        Ipsen New Formulation Know-How shall mean all Know-How that is included within Ipsen New Formulation Technology.

 

1.47        Ipsen New Formulation Patent Rights shall mean all Patent Rights that are included within Ipsen New Formulation Technology.

 

1.48        Ipsen New Formulation Technology shall mean all Patent Rights and Know-How that (i) Ipsen or any of its Affiliates owns or Controls at any time after the Effective Date and during the Term and (ii) have been determined pursuant to, and in accordance with, the provisions of Section 2.7 hereof to be necessary or useful to the development of a new formulation for any Licensed Product that is the subject of any evaluation pursuant to Section 2.7.  Notwithstanding the foregoing provisions of this definition, the term “Ipsen New Formulation Technology” shall not include any Ipsen Licensed Patent Rights or any Ipsen Licensed Know-How.

 

1.49        Ipsen Ongoing Pre-Clinical Studies shall have the meaning set forth in Section 6.2.

 

1.50        Ipsen Patent Rights shall mean the Ipsen Ghrelin Patent Rights.  In addition, the term “Ipsen Patent Rights” shall be deemed automatically modified to include the Ipsen [          ]* Patent Rights if and to the extent that Ipsen obtains an exclusive license to the Ipsen [          ]* Patent Rights from [          ]*.

 

1.51        Ipsen [          ]* Patent Rights shall mean all Patent Rights in connection with the [          ]* Patent Application that Ipsen or any of its Affiliates owns or Controls at any time during the Term.

 

1.52        Ipsen Technology shall mean all Ipsen Know-How and Ipsen Patent Rights.

 

1.53        Joint Know-How shall mean Know-How, whether or not patentable, conceived, created, made, generated or developed jointly by employees of Licensee and Ipsen or any of its Affiliates (with or without a third party) as a result of the research or

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

7

 

CONFIDENTIAL

 

Development activities of the Parties pursuant to, or contemplated under, this Agreement.  The term “Joint Know-How” shall include all Joint Inventions.

 

1.54        Joint Patent Rights shall mean Patent Rights that claim (i) any Joint Invention or (ii) any Joint Know-How.

 

1.55        Know-How shall mean technical and other information, including information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, inventions, methods, models, assays, research plans, procedures, designs for experiments and tests and results of experimentation and testing (including results of research or Development or other developments), formulations, processes (including manufacturing processes, specifications and techniques), laboratory records, chemical, pharmacological, toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports, manufacturing data, pre-clinical data and summaries and information contained in submissions to, and information from, ethical committees and Health Agencies, including documents containing any of the above.

 

1.56        Licensed Product Claim shall mean, for a given Licensed Product in a given country of the Territory, a Valid Claim of Ipsen Patent Rights, Ipsen [          ]* Patent Rights (to the extent not included within Ipsen Patent Rights), Ipsen Future Patent Rights or Joint Patent Rights that Covers such Licensed Product in such country.

 

1.57        Licensed Product shall mean (i) any Ipsen Ghrelin Product or (ii) any [          ]* that is covered by a Valid Claim of any issued patent or patent application included within Ipsen Patent Rights or Joint Patent Rights.

 

1.58        Licensed Rights shall have the meaning set forth in 2.1

 

1.59        Licensee shall have the meaning set forth in the preamble to this Agreement.

 

1.60        Licensee Indemnitees shall have the meaning set forth in Section 15.1.

 

1.61        Licensee Joint Technology Rights shall mean all of Licensee’s right, title and interest in and to the Joint Patent Rights and the Joint Know-How.

 

1.62        Licensee Know-How shall mean all Know-How that Licensee or any of its Affiliates owns, Controls or otherwise has in-licensed at any time during the Term.  Notwithstanding the foregoing provisions of this definition, the term “Licensee Know-How” shall not include Ipsen Licensed Know-How, Ipsen New Formulation Know-How and Joint Know-How.

 

1.63        Licensee Patent Rights shall mean all Patent Rights that Licensee or any of its Affiliates owns, controls or otherwise has in-licensed at any time during the Term.  Notwithstanding the foregoing provisions of this definition, the term “Licensee Patent Rights” shall not include Ipsen Licensed Patent Rights, Ipsen New Formulation Patent Rights and Joint Patent Rights.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

8

 

CONFIDENTIAL

 

1.64        Licensee Technology shall mean all Licensee Know-How and Licensee Patent Rights.

 

1.65        Licensee Trademark shall have the meaning attributed to it under Section 10.1.

 

1.66        Losses shall have the meaning set forth in Section 15.1.

 

1.67        Manufacturing Cost shall have the meaning set forth in the Clinical Supply Agreements.

 

1.68        NDA Filing shall mean a New Drug Application filed as a result of activities under this Agreement with the FDA, or the equivalent application to the equivalent agency in any other country of the Territory, the filing of which is necessary to market and sell a Licensed Product, including all amendments and supplements to any of the foregoing.

 

1.69        Necessary Third Party IP Rights shall mean (i) any Valid Claim of Patent Rights owned or controlled by a third party which would be Infringed by the use or practice of the Ipsen Licensed Technology, Ipsen Future Technology or the Ipsen New Formulation Technology (if and to the extent licensed to Licensee) to research, develop, manufacture, market, promote, use, sell, import or export any Licensed Product in any country of the Territory or (ii) any Patent Rights or Know How owned or controlled by a third party (other than Patent Rights already within the scope of the foregoing clause (i) of this definition) that (1) are reasonably necessary to enable the research, development, manufacture, use or commercialization of a License Product in any country of the Territory, (2) are reasonably likely to materially reduce the risks or the timetable for the development of a License Product in any country of the Territory or (3) are reasonably likely to materially reduce the commercialization risk, or materially increase the anticipated Net Sales, of a Licensed Product in any country of the Territory.

 

1.70        Net Sales shall mean Gross Sales less deductions (not otherwise taken into account) for the [          ]*

 

In the event that a Licensed Product is sold as a component of a Bundled Product, then Net Sales shall be determined by multiplying the Net Sales of the Bundled Product by the fraction [          ]* where [          ]* equals the average selling price of such Licensed

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

9

 

CONFIDENTIAL

 

Product sold separately in finished form and [          ]* equals the aggregate average selling price of the relevant other product(s) included in such Bundled Product sold separately in finished form, in each case in the relevant country in which sales of such Bundled Product were made, during the same Accounting Period and in similar volumes.  In the event that no separate sale of such Licensed Product is made during the applicable Accounting Period in similar volumes and in the relevant country in which the sale of such Bundled Product was made and that there are separate sales of the relevant other product(s) included in such Bundled Product in similar volumes and in the relevant country in which the sale of such Bundled Product was made, then Net Sales shall be determined by multiplying the Net Sales of the Bundled Product by the fraction [          ]*, where [          ]* equals the average selling price of the Bundled Product for the country in which sales were made.  In the event that no separate sale of either such Licensed Product or the relevant other product(s) is made during the applicable Accounting Period in similar volumes and in the relevant country in which the sale of such Bundled Product was made, then Net Sales shall be determined by multiplying the Net Sales of the Bundled Product by the fraction [          ]*, where [          ]* equals the fully absorbed cost of manufacturing such Licensed Product and [          ]* equals the full absorbed cost of manufacturing the relevant other product(s).

 

1.71        Non-Breaching Party shall have the meaning set forth in Section 14.2.

 

1.72        Party shall mean, individually, IPSEN PHARMA S.A.S. or RHYTHM PHARMACEUTICALS, INC., and “Parties” shall mean collectively, IPSEN PHARMA S.A.S. and RHYTHM PHARMACEUTICALS, INC.

 

1.73        Patent Rights shall mean all rights under any patent or patent application in any country of the world, including any substitution, extension or supplementary protection certificate, reissue, re-examination, renewal, division, continuation or continuation-in-part thereof.

 

1.74        [          ]* shall mean [          ]*.

 

1.75        [          ]* Patent Application shall mean [          ]*.

 

1.76        Phase I Clinical Trial shall mean a human clinical trial normally conducted in healthy volunteers with the aim of establishing the pharmacokinetic, pharmacodynamic and early safety profile.

 

1.77        Phase II Clinical Trial shall mean a human clinical trial that is required for Regulatory Approval where a product is tested in a limited number of patients for the purpose of establishing dose ranging and/or first indication of efficacy of product for a therapeutic or prophylactic use.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

10

 

CONFIDENTIAL

 

1.78        Phase III Clinical Trial shall mean a pivotal multi-center human clinical trial in a large number of patients to establish safety or efficacy in the particular claim and indication tested and required to obtain Regulatory Approval.

 

1.79        Phase III Initiation shall mean the date when a Licensed Product is first administered to a patient in the first Phase III Clinical Trial in the Territory.

 

1.80        Publication Eligible Material shall have the meaning set forth in Section 12.1.

 

1.81        Receiver shall have the meaning set forth in Section 11.1.

 

1.82        Regulatory Approval shall mean any and all approvals, licenses, registrations or authorizations (including pricing and reimbursement approvals) whether or not conditional, that are granted by FDA, EMEA or other Regulatory Authority and are necessary for the commercial sale of Licensed Product in a regulatory jurisdiction in the Territory and obtained as a result of activities under this Agreement.

 

1.83        Regulatory Authority shall mean any national, supra-national (e.g., the FDA, the European Commission, the Council of the European Union, or the European Medicines Agency (“EMEA”)), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity in any jurisdiction of the Territory involved in the granting of Regulatory Approval for pharmaceutical products.

 

1.84        ROW shall mean [          ]*.

 

1.85        Royalty Term shall mean for each Licensed Product and each country of the Territory, (a) the period of time commencing on the First Commercial Sale in such country of such Licensed Product and ending on the tenth (10th) anniversary of such First Commercial Sale and (b) any period of time after such tenth (10th) anniversary during which there is a Licensed Product Claim in such country with respect to such Licensed Product.

 

1.86        Section 2.10 Negotiation Period shall have the meaning set forth in Section 2.10.

 

1.87        Sublicense Agreement shall mean any agreement entered into with a third party whereby such third party is granted a sublicense under the Licensed Rights or such third party is granted an option to acquire a sublicense under the Licensed Rights. Notwithstanding anything express or implied in the foregoing provisions of this definition, the term “Sublicense Agreement” shall not include any agreement entered into with a third party whereby such third party is granted the right or option to purchase its supply of Licensed Product in finished form from Licensee, its Affiliates or Sublicensees for resale unto the market, unless, as a partial or full consideration for such purchase, such third party has a payment obligation to Licensee, its Affiliates or Sublicensees that is a percentage of such third party’s net sales, including without limitation a royalty obligation.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

11

 

CONFIDENTIAL

 

1.88        Sublicensee means a third party (other than an Affiliate of Licensee) that has entered into a Sublicense Agreement.

 

1.89        Sublicensing Revenue shall mean any upfront option payments, upfront license fee payments (excluding the fair market value of equity sold, funding for the sole purpose of supporting identified and planned research and development works relating to the Licensed Products, transfer of goods and materials at cost plus an industry standard premium, bona fide loans and bona fide payments to reimburse Licensee or any of its Affiliates for patent prosecution costs incurred in connection with Licensed Products) or milestone payments (including without limitation milestone payments relating to research, development, regulatory or commercial events) to be paid by a Sublicensee to Licensee or any of its Affiliates pursuant to a Sublicense Agreement if and to the extent that such upfront option payments, upfront license fee payments and milestone payments are consideration for any sublicense under the Licensed Rights that is granted pursuant to such Sublicense Agreement or any option granted under such Sublicense Agreement to acquire such sublicense.

 

1.90        Term shall have the meaning set forth in Section 14.1.

 

1.91        Territory shall mean [          ]*.

 

1.92        Unlicensed Product shall mean, with respect to any Licensed Product in any given country within the Territory, any product or pharmaceutical composition that (A) contains [          ]* as such Licensed Product, and (B) is commercially available in such country other than as a result of the licenses granted by Ipsen to Licensee pursuant to this Agreement.

 

1.93        Valid Claim shall mean a claim in any (a) unexpired and issued Patent Right that has not been dedicated to the public, disclaimed, revoked or held invalid by a final unappealable decision or unappealed decision of a court of competent jurisdiction after the period for filing an appeal has expired or (b) pending patent application which patent application has been on file with the application patent office for no more than [          ]* from the earliest date from which the patent application was filed or claims earliest priority.

 

1.94        Withholding Party shall have the meaning set forth in Section 5.4.

 

ARTICLE 2  GRANT OF RIGHTS

 

2.1          License Grants.  Subject to the terms of this Agreement, Ipsen, for and on behalf of itself and all of its Affiliates, hereby grants to Licensee and its Affiliates the following rights (the “Licensed Rights”):

 

-               an exclusive (even as to Ipsen and its Affiliates) right and license in all countries of the Territory, under the Ipsen Technology and the Ipsen Joint Technology Rights, to research, develop, register, use, make, have made, import, export, market, distribute, offer for sale and sell Licensed Product in the Territory for any and all uses and fields of use (it being understood and agreed that,

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

12

 

CONFIDENTIAL

 

notwithstanding the foregoing exclusive grant to Licensee, Licensee hereby authorizes and consents to the exercise by Ipsen and its Affiliates of any and all rights under the Ipsen Technology and the Ipsen Joint Technology Rights if and to the extent necessary for the sole purpose of Ipsen performing its obligations under this Agreement), and

 

-               a non-exclusive right and license in all countries of the Territory under the Ipsen [          ]* Patent Rights (to the extent that the Ipsen [          ]* Patent Rights are not included within the Ipsen Patent Rights) to research, develop, register, use, make, have made, import, export, market, distribute, offer for sale and sell Licensed Product in the Territory for any and all uses and fields of use, and

 

-               a non-exclusive right and license in all countries of the Territory, under the Ipsen Future Technology, to research, develop, register, use, make, have made, import, export, market, distribute, offer for sale and sell Licensed Product in the Territory for any and all uses and fields of use.

 

2.2          Rights retained by Ipsen.  All rights in and to the Ipsen Technology, Ipsen Joint Technology Rights, the Ipsen Future Technology and the Ipsen [          ]* Patent Rights not expressly granted to Licensee under this Agreement are reserved exclusively to Ipsen and its Affiliates.

 

2.3          Sublicenses.  The rights and licenses granted to Licensee under Section 2.1 shall include the right to grant sublicenses under the Licensed Rights and shall also include the right to grant to a Sublicensee the right to grant further sublicenses to the extent of the Licensed Rights so sublicensed to such Sublicensee. If Licensee or any of its Affiliates enters into a Sublicense Agreement, Licensee shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the applicable Sublicensee to the same extent as they apply to Licensee with respect to, and to the extent, of the Licensed Rights so sublicensed. Licensee shall assume full responsibility for the performance of all obligations so imposed on such Sublicensee and will itself account to Ipsen for all payments due under this Agreement by reason of such Sublicense Agreement.  Upon execution of any Sublicense Agreement, Licensee shall provide Ipsen with the financial terms of such Sublicense Agreement for the purposes of evaluating the Share of Sublicensing Revenue owed to Ipsen as per Section 3.4 of this Agreement.

 

2.4          Contractors.  The rights and licenses granted to Licensee under Section 2.1 shall include the right to grant rights to Contractors under Licensed Rights, in whole or in part, and shall also include the right to grant to any direct or indirect third party Contractors the right of such Contractors to further subcontract such Licensed Rights to another third party. If Licensee or any of its Affiliates enters into an agreement with a Contractor pursuant to this Section 2.4, Licensee shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the Contractor to the same extent as they apply to Licensee with respect to, and to the extent, of the rights granted. Licensee shall assume full responsibility for the performance of all obligations so imposed on Contractor and will itself account to Ipsen for all payments due under this Agreement by reason of such subcontract.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

13

 

CONFIDENTIAL

 

2.5          Intellectual Property Rights of Ipsen Affiliates.  In the event that any of the intellectual property rights granted by Ipsen and its Affiliates to Licensee and its Affiliates pursuant to Section 2.1 above are owned or Controlled by any Affiliate of Ipsen and not by Ipsen, Ipsen hereby agrees to take such action as may be required (including, without limitation, exercising control over such Affiliate) to ensure that Licensee and its Affiliates, can fully enjoy, exploit and exercise all of their respective rights under this Agreement with respect to such intellectual property rights to the same extent as if such Affiliate were a party to this Agreement.

 

2.6          Prohibited Uses and Activities

 

2.6.1       Ipsen shall not use or practice any Licensed Rights in contravention or violation of the rights thereunder or thereto granted to Licensee pursuant to Section 2.1.  Ipsen shall not grant licenses or otherwise transfer any rights to any person or entity (other than Licensee and its Affiliates) if and to the extent that any such grant or other transfer would violate, contravene, conflict with, or be inconsistent with, the rights granted to Licensee pursuant to Section 2.1 hereof.

 

2.6.2       During [          ]*, (i) neither Ipsen nor its Affiliates shall research, seek to discover, develop, make, have made, use, distribute, market, sell or otherwise commercialize any Licensed Product or any Unlicensed Product except if and to the extent expressly provided or permitted in this Agreement and in accordance with the terms of this Agreement and (ii) neither Ipsen nor its Affiliates shall grant to any person (other than Licensee and its Affiliates) any right or license to discover, develop, make, have made, use, distribute, market, sell or otherwise commercialize any Licensed Product or Unlicensed Product except if and to the extent expressly provided or permitted in this Agreement and in accordance with the terms of this Agreement.

 

2.6.3       During [          ]*, (i) neither Ipsen nor its Affiliates shall research, seek to identify, develop, make, have made, use, distribute, market, sell or otherwise commercialize any Competing Product for the treatment of any of the indications for which Licensee intends to develop the relevant Licensed Product (with which such Competing Product is likely to compete) as set forth in the Initial Development Plan and (ii) neither Ipsen nor its Affiliates shall grant to any person (other than Licensee and its Affiliates) any right or license to research, seek to discover, develop, make, have made, use, distribute, market, sell or otherwise commercialize any Competing Product for the treatment of any such indications.

 

2.6.4       During [          ]*, (i) neither Ipsen nor its Affiliates shall use or practice any Ipsen Technology or any Ipsen Joint Technology Rights, for the purpose of, or in connection with, discovering, identifying, researching, developing, making, having made, using, distributing, marketing, selling or otherwise commercializing any Competing Product and (ii) neither Ipsen nor its

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

14

 

CONFIDENTIAL

 

Affiliates shall grant to any person (other than Licensee or any of its Affiliates) any right or license to use or practice any Ipsen Technology or any Ipsen Joint Technology Rights, for the purpose of, or in connection with, discovering, identifying, researching, developing, making, having made, using, distributing, marketing, selling or otherwise commercializing any Competing Product.

 

2.7          Ipsen New Formulation Technology

 

2.7.1       At the written request of Licensee made at any time during [          ]* (such request being accompanied by [          ]*), Ipsen or any of its Affiliates shall undertake an evaluation of Patent Rights and Know-How owned or Controlled by Ipsen or any of its Affiliates that are not included within Ipsen Technology, Joint Patents or Joint Know-How and that the Parties, acting reasonably and in good faith, believe may be necessary or useful to the development of a new formulation for any Licensed Product that is specifically identified by Licensee (the “Evaluation Formulation Technology”).  Any such evaluation shall be conducted by Ipsen or any of its Affiliates pursuant to an agreement to be negotiated and entered into by the Parties acting reasonably and in good faith (the “Formulation Technology Evaluation Agreement”).  It is hereby understood and agreed by the Parties that the Formulation Evaluation Agreement shall provide that, at Ipsen’s discretion, the actual activities required in connection with such evaluation may be conducted by a contract research organization mutually acceptable to the Parties.   In the event that, based on the results of such evaluation, the Parties, acting reasonably and in good faith, identify any Evaluation Formulation Technology that is necessary or useful to the development of a new formulation for any such Licensed Product specifically identified by Licensee, (i) any such Evaluation Formulation Technology shall be included within the definition of, and treated for all purposes of this Agreement as, Ipsen New Formulation Technology and (ii) the Parties, acting reasonably and in good faith, shall negotiate the terms of, and execute and deliver, a license agreement pursuant to which Ipsen and its Affiliates would grant to Licensee an exclusive (even as to Ipsen and its Affiliates) right and license in all countries of the Territory, under such Ipsen New Formulation Technology, to research, develop, use, make, have made, import, export, market, distribute, offer for sale and sell Licensed Products.  Such license rights shall be exclusive only with respect to Licensed Products and Ipsen shall not be prohibited from using or granting such Ipsen New Formulation Technology for any compound or product that is not a Licensed Product, a Competing Product or an Unlicensed Product.  Any such exclusive license shall include the right grant sublicenses under such license rights.

 

2.7.2       The obligation of the Parties to negotiate a license agreement pursuant to Section 2.7.1 shall have as an objective to reach good faith agreement on terms that are scientifically and commercially reasonable.  The Parties hereby acknowledge and agree that, in reaching agreement on the appropriate royalty rate applicable to such exclusive license under Ipsen New Formulation Technology, the Parties shall take into account [          ]*

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

15

 

CONFIDENTIAL

 

[          ]* and [        ]*.  Notwithstanding anything expressed or implied in the foregoing provisions of this Section 2.7 to the contrary, in no event shall the royalty rate applicable to Net Sales of any Licensed Product with a formulation developed with, or covered by, all or any portion of the Ipsen New Formulation Technology exceed [          ]*.

 

2.8          [Intentionally Omitted.]

 

2.9          [Intentionally Omitted.]

 

2.10        Ipsen’s Right of Non-Exclusive Negotiation for Licensed Product

 

2.10.1     Prior to Licensee entering into any Sublicense Agreement with a third party (a “Potential Sublicensee”) pursuant to which Licensee shall grant a sublicense under the Licensed Rights to such Potential Sublicensee to develop and/or commercialize one or more Licensed Products (collectively, the “Sublicensed Products” and each individually a “Sublicensed Product”) for all or part of the Territory (all or any part of the Territory covered by any such Sublicense Agreement being hereinafter referred to as the “Sublicensed Territory”) and prior to Licensee entering into any exclusivity agreement with any Potential Sublicensee relating to the exclusive negotiation of any such Sublicense Agreement, (i) Licensee shall notify Ipsen in writing that Licensee is willing to enter into non-exclusive negotiations with Ipsen for the grant by Licensee to Ipsen of commercialization rights to such Sublicensed Products for the Sublicensed Territory and (ii) Licensee shall comply with all of the provisions set forth below in this Section 2.10.1.  As soon as practicable (but in any event within [          ]* of receipt by Ipsen of such notice from Licensee), Ipsen will respond to Licensee in writing regarding Ipsen’s interest in entering into such non-exclusive negotiations.  If Ipsen responds to Licensee in writing that it is not interested in entering into such non-exclusive negotiations, then all obligations of the Parties under this Section 2.10 with respect to such Sublicensed Products in the Sublicensed Territory shall terminate and be of no further force or effect, both at that time and in the future, unless Licensee does not enter into a definitive Sublicense Agreement with a Potential Sublicensee within [           ]* after the date that Ipsen last delivered a written response to Licensee stating that Ipsen was not interested in entering into such non-exclusive negotiations, in which case the Party’s respective rights and obligations under this Section 2.10 with respect to such Sublicensed Products in the Sublicensed Territory shall once again become applicable at that time.  If Ipsen responds to Licensee in writing that it is interested in entering into such non-exclusive negotiations, the Parties will promptly commence non-exclusive, good faith negotiations through and until the earlier of (1) [          ]* following the date that Ipsen gives such written notice to Licensee, provided that Licensee may elect, in its sole and absolute discretion, to have the period covered by this clause (1) be longer than [          ]* by giving written notice of such election to Ipsen (which written

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

16

 

CONFIDENTIAL

 

notice shall specify the length of such period), (2) the date that the Parties jointly determine and agree to end such negotiations and (3) the date that Ipsen notifies Licensee in writing that Ipsen does not want to continue negotiations (the period of such negotiations being hereinafter referred to as the “Section 2.10 Negotiation Period”).  Notwithstanding anything express or implied in the foregoing provisions of this Section 2.10.1 to the contrary, (A) Licensee retains the right to terminate any such negotiations with Ipsen at any time prior to [          ]* if Licensee makes a determination, in its sole and absolute discretion, that Licensee is no longer considering granting commercialization rights to such Sublicensed Products to Ipsen and any Potential Sublicensees and (B) Licensee shall have the right to conduct discussions or negotiations with Potential Sublicensees prior to, simultaneously with, and/or after termination of, the negotiations with Ipsen, provided that Licensee shall not enter into a definitive agreement with any of such Potential Sublicensees until after [          ]*.  If upon [          ]*, Licensee and Ipsen shall not have entered into a definitive agreement pursuant to which Licensee has granted to Ipsen commercialization rights to such Sublicensed Products, then Licensee will be free at any time thereafter to enter into any definitive agreement with a Potential Sublicensee pursuant to which Licensee grants to such Potential Sublicensee any commercialization rights to such Sublicensed Products in the Sublicensed Territory; provided, however, that (i) Licensee shall not enter into any such definitive agreement with a Potential Sublicensee if the terms of such definitive agreement are less favorable to Licensee and its business than the last terms with respect to such Sublicensed Products that were proposed by Ipsen in writing during the applicable Section 2.10 Negotiation Period and (ii) if Licensee does not enter into a definitive Sublicense Agreement with a Potential Sublicensee within [          ]*, the Party’s respective rights and obligations under this Section 2.10 with respect to such Sublicensed Products in the Sublicensed Territory shall once again become applicable at that time.

 

2.10.2     Notwithstanding anything express or implied in any of the provisions of Section 2.10.1 to the contrary, this Section 2.10 shall automatically terminate upon the earlier to occur of (x) the closing of the Licensee’s initial public offering or (y) the occurrence of a Change of Control of Licensee.  For purposes hereof, the term “Change of Control” shall mean, with respect to Licensee, (i) any merger or consolidation involving Licensee or any sale of outstanding shares of capital stock of Licensee, if the stockholders of Licensee immediately prior to the consummation of such merger, consolidation or sale of outstanding shares no longer hold at least a majority of the issued and outstanding shares of capital stock of Licensee immediately after the consummation of such merger, consolidation or sale of outstanding shares and (ii) the sale of all or substantially all of the assets of Licensee.  For purposes of clarification, (A) any equity financing or any other transaction by Licensee pursuant to which Licensee directly issues shares of its capital stock shall not be a transaction subject to

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

17

 

CONFIDENTIAL

 

clause (i) of this Section 2.10.2, and (B) neither Licensee nor Ipsen shall have any rights or obligations under Section 2.10.1 in connection with any Change of Control of Licensee (it being understood and agreed that a Change of Control of Licensee is not the type of transaction that the Parties envision as triggering the provisions of Section 2.10.1).

 

2.11        Third Party Payments by Ipsen.  Ipsen shall make payment of all license fees, milestone payments, royalty payments and other payments that Ipsen or any of its Affiliates is required to pay under or in connection with any agreement with a third party pursuant to which Ipsen or any of its Affiliates acquires or has acquired Patent Rights (including, without limitation, the Ipsen [          ]* Patent Rights) or Know How or other intellectual property rights licensed or sublicensed by Ipsen to License and its Affiliates pursuant to this Agreement.

 

ARTICLE 3  MILESTONE PAYMENTS; PAYMENT OF SHARE OF SUBLICENSING REVENUES

 

3.1          Subject to the provisions of this Section 3.1 and Section 3.5 below, Licensee shall pay to Ipsen the following non-refundable and non-creditable amounts upon the occurrence of the following development milestones with respect to an Ipsen Ghrelin Product:

 

	
Development Milestones
    	
 
    	
Amount
    	
 
    
	
[          ]*
    	
 
    	
[          ]
    	
*
    
	
[          ]*
    	
 
    	
[          ]
    	
*
    
	
[          ]*
    	
 
    	
[          ]
    	
*
    
	
[          ]*
    	
 
    	
[          ]
    	
*
    
	
[          ]*
    	
 
    	
[          ]
    	
*
    
	
[          ]*
    	
 
    	
[          ]
    	
*
    

 

Each milestone payment by Licensee to Ipsen pursuant to the foregoing provisions of this Section 3.1 shall be paid only once upon the first occurrence of the applicable development milestone, regardless of how many times a particular development milestone is achieved and notwithstanding that more than one Ipsen Ghrelin Product achieves a given development milestone.  Without limiting the generality of the foregoing sentence, in no event shall the aggregate amount of milestone payments made by Licensee to Ipsen pursuant to this Section 3.1 under any circumstances exceed [          ]*.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

18

 

CONFIDENTIAL

 

Licensee shall promptly inform Ipsen of the occurrence of any of the above development milestones and Licensee shall make payment of any milestone payment that Licensee is required to make pursuant to this Section 3.1 within [          ]* after the achievement of the applicable development milestone.

 

3.2          Subject to the provisions of this Section 3.2 and Section 3.5 below, Licensee shall pay to Ipsen the following non-refundable and non-creditable amounts upon the occurrence of the following commercialization milestones with respect to an Ipsen Ghrelin Product:

 

	
Commercialization Milestones
    	
 
    	
Amount
    	
 
    
	
[          ]*
    	
 
    	
[          ]
    	
*
    
	
[          ]*
    	
 
    	
[          ]
    	
*
    

 

Each milestone payment by Licensee to Ipsen pursuant to the foregoing provisions of this Section 3.2 shall be paid only once upon the first occurrence of the applicable commercialization milestone, regardless of how many times a particular commercialization milestone is achieved and notwithstanding that more than one Ipsen Ghrelin Product achieves a given commercialization milestone.  Without limiting the generality of the foregoing sentence, in no event shall the aggregate amount of milestone payments made by License to Ipsen pursuant to this Section 3.2 under any circumstances exceed [          ]*.

 

Licensee shall promptly inform Ipsen of the occurrence of any of the above commercialization milestones and Licensee shall make payment of any milestone payment that Licensee is required to make pursuant to this Section 3.2 within [          ]* after the end of the calendar quarter during which the applicable commercialization milestone is achieved.

 

3.3          Subject to the provisions of Section 3.5 below, in the event that Licensee or any of its Affiliates, on the one hand, and Sublicensee, on the other hand, execute and deliver a Sublicense Agreement, Licensee shall make payment to Ipsen of the Share (as defined in Section 3.4 below) of all Sublicensing Revenues actually received by Licensee or any of its Affiliates under such Sublicense Agreement.  Licensee shall make any payment that Licensee is required to make to Ipsen pursuant to this Section 3.3 within [          ]* of the end of the Accounting Period in which Licensee or any of its Affiliates actually received any such Sublicensing Revenues.

 

3.4          The Share shall depend on the date of execution of the relevant Sublicense Agreement, as follows:

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

19

 

CONFIDENTIAL

 

	
Date of execution of the Sublicense Agreement
    	
 
    	
Share
    	
 
    
	
[          ]*
    	
 
    	
[          
    	
]*
    
	
[          ]*
    	
 
    	
[          
    	
]*
    
	
[          ]*
    	
 
    	
[          
    	
]*
    

 

For purposes of clarification,  “completion” shall mean [          ]*.

 

Notwithstanding anything express or implied in the foregoing provisions of this Section 3.4 or elsewhere in this Agreement to the contrary, it is hereby understood and agreed that if Licensee or any of its Affiliates enters into Sublicense Agreement pursuant to which the applicable Sublicensee is granted an option that entitles such Sublicensee upon exercise of such option to obtain a sublicense under the Licensed Rights, Ipsen’s Share of Sublicensing Revenues should be calculated under this Section 3.4 as follows :

 

(i) Ipsen’s Share of any upfront option fees actually received by Licensee or any of its Affiliates in connection with the grant of such option shall be [          ]*, and

 

(ii) Ipsen’s Share under this Section 3.4 of any upfront license fees and milestone payments actually received by Licensee or any of its Affiliates in connection with the grant of any such sublicense under the Licensed Rights upon exercise of such option shall be [          ]*.

 

For example, in the event that [          ]*

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

20

 

CONFIDENTIAL

 

[          ]*, then [          ]*.

 

3.5          Notwithstanding anything express or implied in the foregoing provisions of this Article 3, in the event that, but for the provisions of this Section 3.5, the same development or commercialization milestones would trigger the payment of a milestone payment pursuant to Sections 3.1 through 3.2 hereof and also the payment pursuant to Sections 3.3 and 3.4 of a Share of any Sublicensing Revenue actually received by Licensee or any of its Affiliates in connection with such development or commercialization milestones, Licensee shall pay to Ipsen [          ]*.

 

ARTICLE 4  PAYMENTS BASED ON SALES OF LICENSED PRODUCT

 

4.1          Royalties.  In consideration for the rights and license granted under this Agreement, Licensee shall, subject to the provisions of Sections 0, 4.2 and 4.3 below, pay royalties to Ipsen based upon Net Sales of any given Licensed Product in any given country in the Territory during the Royalty Term applicable to sales of such Licensed Product in such country, which royalties shall be equal to [          ]* of such Net Sales.  For purposes of clarification, the determination of the amount of royalties due Ipsen pursuant to this Section 4.1 shall be made on a Licensed Product-by-Licensed Product basis and on a country-by-country basis.  Payment of royalties due to Ipsen pursuant to this Article 4 shall be made in accordance with the provisions of Article 5 hereof.

 

Adjustments related to Unlicensed Products.  Notwithstanding anything express or implied in Section 4.1 to the contrary and subject to Section 4.3 hereof, if, during the Royalty Term in a given country of the Territory, (i) there is no Valid Claim of an issued patent within Ipsen Patent Rights or Joint Patent Rights that Covers the sale of a Licensed Product in such country, and (ii) the aggregate sales revenue in such country of Unlicensed Products (expressed in the currency of such country) constitute more than [          ]*of the market share with respect to the aggregate sales revenue of such Unlicensed Products and such Licensed Product in such country (expressed in the currency of such country), then Licensee shall have the right to calculate royalty payments due to Ipsen pursuant to this Agreement by including only [          ]*of the amount of Net Sales that would

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

21

 

CONFIDENTIAL

 

have otherwise been included for such Licensed Product in such country to calculate such royalty payments.  For the avoidance of doubt, such adjustment of royalties shall apply only if the applicable Unlicensed Products contain the same [          ]* as the applicable Licensed Product. In case of a disagreement between the Parties on the market share of one or more Unlicensed Products in any country of the Territory, the Parties agree to refer such dispute to arbitration pursuant to Article 16.

 

4.2          Adjustments Related to Necessary Third Party IP Rights.  Subject to Section 4.3 below, on a Licensed Product-by-Licensed Product basis and on a country-by-country basis, (i) if Licensee or any of its Affiliates or Sublicensees is obligated to remit payments (the “Necessary Third Party IP Rights Payments”) to any third party in accordance with the terms of any license entered into by Licensee or any of its Affiliates or Sublicensees with respect to Necessary Third Party IP Rights owned or controlled by such third party (and, in the case of payments required to be so remitted by any such Sublicensee, royalties otherwise due from such Sublicensee to Licensee or any of its Affiliates are reduced as a result of any such required remittance by such Sublicensee) and/or (ii) if (1) Licensee or any of its Affiliates has not obtained a license under Ipsen New Formulation Technology pursuant to Section 2.7 hereof and (2) Licensee or any of its Affiliates or Sublicensees is obligated to remit payments (“Third Party Formulation Technology Payments”) to any third party in accordance with the terms of any license entered into by Licensee or any of its Affiliates or Sublicensees with respect to formulation technology owned or controlled by such third party and used by Licensee or any of its Affiliates and Sublicensees with any Licensed Product (“Third Party Formulation Technology”) (and, in the case of payments required to be so remitted by a Sublicensee, royalties otherwise due from such Sublicensee to Licensee or any of its Affiliates are reduced as a result of any such required remittance by such Sublicensee), Licensee shall be permitted to offset [          ]* of Necessary Third Party IP Rights Payments and/or [          ]* of Third Party Formulation Technology Payments against royalties due to Ipsen under this Agreement with respect to sales of the applicable Licensed Product in the applicable country; provided, however, that (i) any offset of Third Party Formulation Technology Payments shall not result in a reduction of more than [          ]* of the royalty payments that would otherwise have been due to Ipsen under this Agreement in any calendar year with respect to sales of the applicable Licensed Product in the applicable country and (ii) any offset of Necessary Third Party IP Rights Payments shall not result in a reduction of more than [          ]* of the royalty payments that would otherwise have been due to Ipsen under this Agreement in any calendar year with respect to sales of the applicable Licensed Product in the applicable country.  In case Licensee has not been able to offset any allowed amount during any relevant calendar year, no resulting payment shall be due from Ipsen to Licensee as a result of such shortfall, but Licensee shall be entitled to carry over such shortfall to one or more subsequent calendar years and seek to offset the full amount of such shortfall against payments otherwise due to Ipsen in such subsequent calendar year or calendar years (subject always to the limitation set forth in this Section 4.2 and in Section 4.3).

 

4.3          Total Section 4.2 and Section 4.3 Adjustments.  In no event shall the adjustments provided under Sections 0 and 4.2 hereof, applied individually or cumulatively, result in an effective royalty rate in connection with royalty payments to

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

22

 

CONFIDENTIAL

 

Ipsen under this Agreement of less than [          ]* on Net Sales of any Licensed Product in any country in any calendar year during the Royalty Term.

 

ARTICLE 5  PAYMENT, REPORTING, AUDITING

 

5.1          Currency and Conversion.  Subject to the provisions set forth below in this Section 5.1, all payments under this Agreement shall be in US Dollars except for royalty payments with respect to Net Sales made in ROW, which shall be made in Euros. As regards Net Sales in United States of America, Licensee shall calculate Net Sales and calculate and pay corresponding royalties in US Dollars.  Whenever calculations of Net Sales or royalties require conversion from any currency into Euros, Licensee shall convert into Euros the amount of Gross Sales and Net Sales, using the [          ]* exchange rates (as published in the Wall Street Journal European Edition or if no longer available any other sources mutually-agreed by the Parties) of the last working day of each applicable Accounting Period.

 

5.2          Payments and Reporting.  After the First Commercial Sale of Licensed Product in the Territory, Licensee shall calculate royalties quarterly at the end of each Accounting Period [          ]* and shall pay royalties on Net Sales quarterly within [          ]* after the end of each Accounting Period.

 

With each such payment, Licensee shall provide in writing to Ipsen for the relevant Accounting Period at least the following information split by United States of America, and any other countries of the Territory:

 

·                  Gross Sales (expressed in the currency in which the sale of Licensed Product is made, and, for Gross Sales achieved in the ROW, the applicable conversion rates and the resulting amount in Euros, subject to the provisions of Section 5.1 above) on a Licensed Product-by-Licensed Product basis, in unit and in value;

 

·                  Net Sales (expressed in the currency in which the sale of Licensed Product is made, and, for Net Sales achieved in the ROW, the applicable conversion rates and the resulting amount in Euros, subject to the provisions of Section 5.1 above) on a Licensed Product-by-Licensed Product basis, in unit and in value;

 

·                  Total royalty payable (expressed in USD for the USA and in Euros for ROW, subject to the provisions of Section 5.1 above) on a Licensed Product-by-Licensed Product basis.

 

5.3          Late payments. Any payment under Articles 3 and 4 that is not timely paid shall bear interest, to the extent permitted by applicable law, at [          ]*.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

23

 

CONFIDENTIAL

 

5.4          Taxes

 

Each Party shall pay all sales, turnover, income, revenue, value added, and other taxes levied on account of payments accruing or made to it under this Agreement.  Nothing in the foregoing sentence shall be deemed to affect the definition of Manufacturing Cost and/or any right that Ipsen specifically is provided or granted under this Agreement to charge and collect from the other Party the Manufacturing Cost incurred by Ipsen in connection with Licensed Product supplied by such Party to the other Party under the terms and conditions of the Clinical Supply Agreements.

 

If provision is made in law or regulation of any country for withholding of taxes of any type, levies or other charges with respect to any amounts payable under this Agreement to a Party, the other Party (“Withholding Party”) shall promptly pay such tax, levy or charge for and on behalf of the Party to the proper governmental authority, and shall promptly furnish the Party with a signed original certificate of such tax deduction. The Withholding Party shall have the right to deduct any such tax, levy or charge actually paid from payment due by the Party or be promptly reimbursed by the Party if no further payments are due by the Party. Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.

 

5.5          Blocked Countries.  If by reason of law, Licensee is unable to convert to US Dollars a portion of the amount due by it under this Agreement, then Licensee shall notify Ipsen in writing and Licensee shall pay to Ipsen such portion in the currency of any other country designated by Ipsen and legally available to Licensee.

 

5.6          Accounting.  Licensee shall maintain and shall cause its Affiliates, Sublicensees and Contractors to maintain full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all royalties payable under this Agreement. Such books of account shall be kept at their principal place of business. Licensee, its Affiliates, Sublicensees and Contractors shall permit Ipsen, by independent qualified public accountants selected by Ipsen, to examine such books and records at any reasonable time, but not later than [          ]* following the rendering of any corresponding reports, accountings and payments pursuant to this Agreement.  The foregoing right of review may be exercised only once during each [          ]* period. Such accountants may be required by Licensee, its Affiliates, Sublicensees and Contractors to enter into a reasonably acceptable confidentiality agreement, and in no event shall such accountants disclose to Ipsen any information other than such as relates to the accuracy of reports and payments made or due hereunder.  The opinion of said independent accountants regarding such reports, accountings and payments shall be binding on the parties other than in the case of manifest error.  Ipsen shall bear the cost of any such examination and review; provided that if the inspection and audit shows an underpayment of royalty due to Ipsen of more than [          ]* of the amount due for the applicable Accounting Period, then Licensee shall promptly reimburse Ipsen for all costs incurred in connection with such examination and review.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

24

 

CONFIDENTIAL

 

Licensee shall promptly pay to Ipsen the amount of any such underpayment revealed by an examination and review together with late payment interest pursuant to Section 5.3.

 

ARTICLE 6  DEVELOPMENT

 

6.1          Transfer of Ipsen Licensed Technology and Documentation to Licensee.  The Parties agree that, promptly following the Effective Date, at the reasonable request from Licensee, Ipsen shall transfer:

 

-                                            [          ]*

 

At least once each [          ]* during the Term and at such other times as License may reasonably request from time to time during the Term, Ipsen shall transfer to Licensee (i) any and all of the items listed above to the extent that they are in the possession or control of Ipsen and have not previously been transferred to Licensee and (ii) copies of all documents in Ipsen’s possession or under its control relating to any Ipsen Licensed Know-How and electronic copies of all patents and patent applications included within Ipsen Licensed Patent Rights, in each case to the extent not previously transferred to Licensee.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

25

 

CONFIDENTIAL

 

The performance by Ipsen of its obligations under the foregoing provisions of this Section 6.1 shall be at no cost to Licensee.

 

From time to time during the applicable Initial Ipsen Support Period (as defined below), at the reasonable request of Licensee, Ipsen agrees to make available to Licensee, free of charge, those of Ipsen’s employees and consultants that have knowledge and expertise in connection with researching, developing, obtaining regulatory approval for, or creating and prosecuting intellectual property with respect to, Licensed Products, or in connection with the research, development, use or practice of the Ipsen Technology, for purposes of facilitating the transfer of all Ipsen Technology to Licensee or the transfer of any of the items required to be transferred by Ipsen to Licensee pursuant to this Section 6.1. For purposes of this Agreement, the term “Initial Ipsen Support Period” shall mean a period of [          ]* commencing on [          ]*.  Such [          ]* periods may be extended by mutual agreement of the parties, acting reasonably and in good faith.  At Licensee’s request made at any time during the Term following the expiration of the applicable Initial Ipsen Support Period, Ipsen may provide to Licensee, on a case-by-case basis, reasonable assistance with respect to knowledge and expertise in connection with research, developing, obtaining regulatory approval for, or creating and prosecuting intellectual property with respect to the Licensed Products, subject to the Parties agreeing on the scope of such assistance. Such assistance shall be charged to Licensee at the per diem rate of [          ]* for internal costs and at cost for external costs.

 

6.2          Responsibility and Decision-Making Authority; Development Costs.  Unless otherwise agreed in any definitive agreement executed by the Parties pursuant to Section 2.10, Licensee shall have the sole right, responsibility and decision-making authority for all aspects of Development of Licensed Products in the Territory, and shall bear all related costs.  Notwithstanding anything express or implied in this Agreement (including, without limitation, this Section 6.2) to the contrary, Ipsen shall continue until completion certain [          ]* that are identified on Appendix C and are ongoing as of the Effective Date under its sole responsibility and decision-making authority (collectively, the “Ipsen Ongoing Pre-Clinical Studies”).

 

6.3          Development Plan.  The Parties have agreed upon the Initial Development Plan.  Licensee shall update and modify the Development Plan from time to time to reflect all Development activities planned by Licensee to obtain Regulatory Approval for each Licensed Product in the Territory, as well as to include any changes or modifications planned by Licensee to such Development activities or to any other aspect of the Development Plan as in effect prior to such changes or modifications.  Licensee shall provide to Ipsen a copy of each such update and modification of the Development Plan.  The obligations of Licensee under this Section 6.3 with respect to each Licensed Product shall terminate upon the First Commercial Sale of such Licensed Product.

 

6.4          Reports.  In addition, on [          ]* after the Effective Date and during the Term, Licensee will provide to Ipsen a written progress report that will describe the Development activities that Licensee has performed or

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

26

 

CONFIDENTIAL

 

6.5          caused to be performed during the preceding [          ]* period. The obligations of Licensee under this Section 6.4 with respect to each Licensed Product shall terminate upon the First Commercial Sale of such Licensed Product.

 

ARTICLE 7  REGULATORY MATTERS AND SAFETY

 

7.1          Responsibility and Decision-Making Authority for Regulatory Affairs.  Unless otherwise agreed in any definitive agreement executed by the Parties pursuant to Section 2.10, Licensee, at its own expense, shall have the sole right, responsibility and decision-making authority for all regulatory affairs in the Territory related to Licensed Product, including the preparation and filing of applications for Regulatory Approval, as well as any or all governmental approvals required to manufacture, or have manufactured, Licensed Product.  Licensee shall file all such applications in its own name or that of its Affiliate.  Licensee, at its own expense, shall have the sole right and responsibility for all communications and dealings with the Regulatory Authorities in the Territory.

 

7.2          Ownership of Regulatory Approvals. Unless otherwise agreed in any definitive agreement executed by the Parties pursuant to Section 2.10, Licensee shall own all Regulatory Approval files and Regulatory Approvals in the Territory.

 

7.3          Pharmaco-vigilance responsibility. Unless otherwise agreed in any definitive agreement executed by the Parties pursuant to Section 2.10, Licensee shall be responsible for reporting to Regulatory Authorities in the Territory any adverse experience and safety issues for Licensed Product in compliance with the requirements of the applicable laws, rules and regulations.

 

7.4          Drug Safety Database. Unless otherwise agreed in any definitive agreement executed by the Parties pursuant to Section 2.10, Licensee shall be responsible for compiling a validated global database that captures all adverse events reported to Licensee from any source and maintaining said database.

 

ARTICLE 8  MANUFACTURE AND SUPPLY

 

8.1          Supply for Development. If requested by Licensee by written notice, Ipsen shall manufacture and supply, or cause to be manufactured and supplied, [          ]* in sufficient quantities to satisfy the reasonable requirements of Licensee and its Sublicensees and Contractors for use of such [          ]* in Development activities with respect to such Licensed Product until the end of [          ]*. Ipsen’s supply of [          ]* to Licensee under this Section 8.1 shall be provided at Ipsen’s Manufacturing Cost. Promptly following Licensee’s notice, the Parties shall enter into a clinical supply agreement and a technical agreement with respect to such clinical supplies (the “Clinical Supply Agreements”)(1). Ipsen’s Manufacturing Cost will

 

(1)  [          ]*

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

27

 

CONFIDENTIAL

 

be agreed upon in the Clinical Supply Agreements (to reflect Ipsen’s actual costs for manufacturing the [          ]* as well as a mechanism for adjusting such Manufacturing Cost in case of increase or decrease of any component of such Manufacturing Cost. The Clinical Supply Agreements will provide for the terms and conditions of the transfer of Ipsen’s manufacturing technology at the end of [          ]*, provided, however, that the Parties agree that such transfer will be made at Licensee’s cost and expense, less an amount equal to the Ipsen Manufacturing Transfer Cost, to be estimated and agreed by the parties in good faith. For the avoidance of doubt, in the event Licensee does not notify Ipsen with its request for the manufacturing by Ipsen of [          ]* pursuant to this Section 8.1, the transfer of manufacturing technology shall be made under the terms and conditions of Section 8.1. Ipsen shall not be obligated to manufacture any quantities of [          ]* pursuant to this Section 8.1 if and to the extent that such quantities will be used by Licensee or any of its Sublicensees or Contractors to make finished Licensed Product for use in any [          ]*.

 

8.2          Transition.  In the event Licensee does not notify Ipsen with its request for Ipsen manufacturing [          ]* to Section 8.1, at the request of Licensee, Ipsen shall provide to Licensee a manufacturing transfer package relating to Ipsen’s existing manufacturing technology of the Licensed Products no later than [          ]* from the date of request by Licensee, and Ipsen shall use [          ]* efforts to transfer to Licensee all Ipsen Licensed Know-How and methods pertaining to the manufacture of [          ]* at Ipsen’s cost and expense (the “Ipsen Manufacturing Transfer Cost”) and Licensee shall use [          ]* efforts to understand and implement such Ipsen Licensed Know-How and methods pertaining to the manufacture of such Licensed Product.

 

8.3          Commercial Supply.  Unless otherwise agreed in any definitive agreement executed by the Parties pursuant to Section 2.10, Licensee shall have the sole right, responsibility and decision-making authority for the manufacture, in accordance with good manufacturing practice, and supply of commercial quantities of Licensed Product in the Territory after receipt of Regulatory Approval therefor in the applicable jurisdiction or jurisdictions.

 

ARTICLE 9  COMMERCIALIZATION

 

9.1          Responsibility and Decision-Making Authority. Unless otherwise agreed in any definitive agreement executed by the Parties pursuant to Section 2.10, Licensee, at its own expense, shall have sole right, responsibility and decision-making authority for the marketing, promotion, sale and distribution of Licensed Product in the Territory under Licensee’s Regulatory Approvals.

 

ARTICLE 10  INTELLECTUAL PROPERTY

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

28

 

CONFIDENTIAL

 

10.1        Trademarks.  Licensee shall identify and select one or more trademarks to be used to register, distribute and promote the Licensed Products in the Territory (collectively, “Licensee Trademarks” and each individually a “Licensee Trademark”) which shall not be the same or confusingly similar to any product of Ipsen.  Unless otherwise agreed between the Parties, Ipsen shall not avail itself of any license on any Licensee Trademark, shall not register or use any Licensee Trademark and shall not license, register or use any other trademark or trade name which is the same as, or confusingly similar to, any Licensee Trademark in any country.  Licensee shall own and, at its cost, shall be responsible for procurement, registration, maintenance and enforcement of all Licensee Trademarks used or registered in connection with any Licensed Product.

 

10.2        Infringements of Trademarks.  Licensee shall have the sole right but not the obligation to initiate proceedings against, or defend claims made by, any person in connection with any Licensee Trademark.  The commencement, strategies, termination, settlement or defense of any action relating to the validity or infringement of Licensee Trademarks shall be decided by Licensee. Any such proceedings shall be at the expense of Licensee.  Any damages or costs recovered by Licensee as a result of any such proceedings or claims, shall be for the sole benefit and account of Licensee.

 

10.3        Patent Right and Know-How Ownership

 

10.3.1     Ipsen shall own all Ipsen Inventions, Licensee shall own all Licensee Inventions, and Ipsen and Licensee shall jointly own all Joint Inventions. Each Party promptly will notify the other Party in writing of (i) any Invention that the notifying Party believes is a Joint Invention and (ii) any Invention for which the notifying Party intends to file a patent application.  Each Party shall require all of its employees and contractors to assign all Inventions made by them to such Party.

 

10.3.2     All right, title and interest in and to Ipsen Licensed Technology are and shall remain vested in Ipsen, subject only to any rights thereto granted by Ipsen to Licensee pursuant to this Agreement, including, without limitation, the Licensed Rights granted by Ipsen to Licensee pursuant to Section 2.1. Notwithstanding anything express or implied in the foregoing provisions of this Section 10.3.2 or elsewhere in this Agreement to the contrary, Ipsen and its Affiliates shall not sell, assign or otherwise transfer or dispose of all or any portion of their respective right, title and interest in and to Ipsen Licensed Technology without having obtained the prior agreement or consent of Licensee, unless (x) the proposed buyer, assignee or other transferee shall have, as a condition precedent to the effectiveness of any such sale, assignment or other transfer or disposition, executed an instrument in writing agreeing to assume all of the agreements and obligations under this Agreement of Ipsen and its Affiliates to the extent applicable to the Ipsen Licensed Technology, or the portion thereof, transferred to such buyer, assignee or other transferee, and (y) any such sale, assignment or other transfer or disposition shall not operate to release Ipsen and its Affiliates from any of its agreements or obligations under this Agreement.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

29

 

CONFIDENTIAL

 

10.3.3     All right, title and interest in and to Licensee Know-How, Licensee Patent Rights and Licensee Joint Technology Rights are and shall remain vested in Licensee.

 

10.3.4     Any and all Joint Know-How and Joint Patent Rights shall be owned by the Parties in equal undivided shares.  Except to the extent otherwise provided elsewhere in this Agreement to the contrary (including, without limitation, the provisions of Section 2.1 pursuant to which Ipsen granted to Licensee an exclusive license to all of Ipsen’s right, title and interest in and to all of the Joint Know-How and Joint Patent Rights for certain uses specified therein), each Party shall be free to use its undivided share of any and all Joint Inventions or any and all Joint Patent Rights without having to obtain the agreement or consent of the other Party, without having to provide notice of such use to the other Party and without having to make any accounting to the other Party for such use or any revenues or profits derived from such use. In addition, except to the extent otherwise provided elsewhere in this Agreement to the contrary, each Party shall be free to sell, assign, license and otherwise transfer or dispose of all or any portion of such Party’s undivided share in any and all Joint Inventions or any and all Joint Patent Rights without having to obtain the agreement or consent of the other Party, without having to provide notice of such sale, assignment, license or other transfer or disposition to the other Party and without having to make any accounting to the other Party for such sale, assignment, license or other transfer or disposition or any revenues or profits derived from such sale, assignment, license or other transfer or disposition; provided, however, that (x) any buyer, assignee, licensee or other transferee of all or any portion of the Joint Inventions and Joint Patent Rights shall take all or the portion of the Joint Inventions and/or Joint Patent Rights so transferred subject to all of the agreements and obligations under this Agreement of the transferring Party (including, without limitation, the exclusive licenses granted by Ipsen to Licensee pursuant to Section 2.1 hereof with respect to certain uses of Ipsen’s right, title and interest to the Joint Inventions and Joint Patent Rights), (y) such buyer, assignee, licensee or other transferee shall, as a condition precedent to the effectiveness of any such sale, assignment, license or other transfer or disposition, execute an instrument in writing agreeing to assume all of the agreements and obligations under this Agreement of the transferring Party to the extent applicable to the Joint Inventions or Joint Patent Rights, or the portion thereof, transferred to such buyer, assignee, licensee or other transferee, and (z) any such sale, assignment, license or other transfer or disposition shall not operate to release the transferring Party from any of its agreements or obligations under this Agreement.  Licensee may use during the Term any and all Joint Inventions and Joint Patent Rights for the purposes contemplated in this Agreement.

 

10.4        Filing — Prosecution and Maintenance of Ipsen Licensed Patent Rights and Licensee Patent Rights.

 

10.4.1     Ipsen shall at its own cost and expense be solely responsible for the filing, prosecution and maintenance of the Ipsen Licensed Patent Rights in the 

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

30

 

CONFIDENTIAL

 

Territory, including the conduct and defense of any claims or proceedings relating to the Ipsen Licensed Patent Rights in the Territory (including but not limited to any interference, reissue or re-examination or opposition proceedings); provided, however, that Ipsen shall (i) provide Licensee with all material documentation and correspondence from, sent to or filed with patent offices in the Territory regarding the Ipsen Licensed Patent Rights, (ii) provide Licensee with a reasonable opportunity to review and comment upon all filings with such patent offices in advance of submissions to such patent offices, and (iii) shall consider, in good faith, incorporating any reasonable comments provided by Licensee with respect to any such filings.  Without limiting the generality of the foregoing provisions of this Section 10.4.1, Ipsen shall at its own cost and expense file, prosecute and maintain Ipsen Licensed Patent Rights in any country in the Territory as reasonably requested by Licensee acting in a reasonable commercial manner with regards the market potential of such country, including the conduct and defense of any claims or proceedings relating to the Ipsen Licensed Patent Rights in such country (including but not limited to any interference, reissue or re-examination or opposition proceedings).  If Ipsen determines in its sole discretion to abandon or not to file, prosecute or maintain any claim, patent or patent application within the Ipsen Licensed Patent Rights in any country in the Territory, including the conduct and defense of any claims or proceedings relating to such claim, patent or patent application (including but not limited to any interference, reissue or re-examination or opposition proceedings), then Ipsen shall provide Licensee with [          ]* prior written notice of such determination, and shall provide Licensee with the opportunity to file, prosecute and maintain such claim, patent or patent application in such country in the name of Licensee (or an Affiliate of Licensee) as assignee, including the conduct and defense of any claims or proceedings relating to such claim, patent or patent application in such country (including but not limited to any interference, reissue or re-examination or opposition proceedings), and Ipsen shall assign to Licensee its entire right in such claim, patent or patent application in such country, and thereafter Licensee shall be responsible for all costs and expenses in connection with the filing, prosecution or maintenance of any such claim, patent or patent application assigned by Ipsen to Licensee pursuant to this Section 10.4.1 and Ipsen shall not be entitled to any compensation of any kind (including, without limitation, any compensation for such assignment) in connection with any such claim, patent or patent application assigned by Ipsen to Licensee.  Ipsen shall also pay for all costs and expenses in connection with any assignment by Ipsen to Licensee of any claim, patent or patent application pursuant to this Section 10.4.1.  Licensee shall upon first request from Ipsen deliver to Ipsen the original of any Regulatory Approval for the purpose of applying for any supplementary protection certificates of any Ipsen Licensed Patent Rights.

 

10.4.2     Licensee shall at its own cost and expense be solely responsible for the filing, prosecution and maintenance of the Licensee Patent Rights, including the conduct and defense of any claims or proceedings relating to the Licensee Patent Rights in the Territory (including but not limited to any interference, reissue or re-examination or opposition proceedings).

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

31

 

CONFIDENTIAL

 

10.4.3     Each Party will take account of the other Party’s interest in the performance of its obligations under this Section 10.4.  Each Party shall provide to the other all assistance reasonably requested by the other Party on all such matters (at the expense of such other Party), including agreeing to and taking all steps and executing all documents necessary to be joined as claimant or defendant in any proceedings in any country.

 

10.5        Filing — Prosecution and Maintenance of Joint Patent Rights.  Unless the Parties otherwise mutually agree in writing, Licensee shall have the first right to file, prosecute and maintain the Joint Patent Rights in any and all countries of the world, including the conduct and defense of any claims or proceedings relating to the Joint Patent Rights in any and all countries of the world (including but not limited to any interference, reissue or re-examination or opposition proceedings), provided however, in the event that Licensee determines in its sole discretion to abandon or not to file, prosecute or maintain any claim, patent or patent application within the Joint Patent Rights in any country of the world, including the conduct and defense of any claims or proceedings relating to such claim, patent or patent application (including but not limited to any interference, reissue or re-examination or opposition proceedings), then Licensee shall provide Ipsen with [          ]* prior written notice of such determination, and Ipsen shall have such right and upon exercise of such right, Ipsen shall have the right to file, prosecute and maintain such claim, patent or patent application in such country, including the conduct and defense of any claims or proceedings relating to such claim, patent or patent application in such country (including but not limited to any interference, reissue or re-examination or opposition proceedings).  In each case under this Section 10.5, the filing Party (A) shall give the non-filing Party a reasonable opportunity to review the text of the application or submission before filing, (B) shall consult with the non-filing Party with respect thereto, (C) shall, prior to filing any application or submission, incorporate any reasonable comments that the non-filing Party shall make on a timely basis to such application or submission and (D) shall supply the non-filing Party with a copy of the application or submission as filed, together with notice of its filing date and serial number and all substantive prosecution.  Each Party shall keep the other advised of the status of the actual and prospective patent filings described above in this Section 10.5 and, upon the request of the other, provide advance copies of any papers related to the filing, prosecution and maintenance of such patent filings.  Licensee shall promptly give notice to Ipsen of the grant, lapse, revocation, surrender, invalidation or abandonment in any country within the Territory of any Joint Patent Rights being prosecuted by Licensee.  Ipsen shall promptly give notice to Licensee of the grant, lapse, revocation, surrender, invalidation or abandonment in any country within the Territory of any Joint Patent Rights being prosecuted by Ipsen.  With respect to all filings under this Section 10.5, the filing Party shall be responsible for payment of all costs and expenses related to such filings (including, without limitation, fees and disbursements of outside legal counsel in connection with such filings), subject to prompt reimbursement from the non-filing Party for [          ]* of all of such costs and expenses.  Either Party may disclaim its interest in any particular patent or patent application included in the Joint Patent Rights, in which case (X) the disclaiming Party shall assign its ownership interest in such patent or patent application to the other Party for no additional consideration, (Y) the Party which is then the sole owner shall be solely responsible for

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

32

 

CONFIDENTIAL

 

all future costs of such patent or patent application and (Z) the disclaiming Party shall hold no further rights thereunder.

 

10.6        Infringement.  Each Party shall give prompt written notice to the other of any suspected or actual Infringement by a third party of all or any portion of the Ipsen Licensed Technology, Licensee Technology, Joint Inventions or Joint Patent Rights that comes to the attention of that Party during the Royalty Term with respect to any and all countries in the Territory.  Licensee shall have the first right but not the obligation to initiate and pursue proceedings against such third party in connection with any such suspected or actual Infringement of all or any portion of the Ipsen Licensed Technology, Joint Inventions or Joint Patent Rights, and Licensee shall have the sole right but not the obligation to initiate and pursue proceedings against such third party in connection with any such suspected or actual Infringement of all or any portion of Licensee Technology.  The commencement, strategies, termination, and settlement of any action or proceedings relating to the validity or suspected or actual Infringement of the Ipsen Licensed Technology, Joint Inventions or Joint Patent Rights, or any portion thereof, shall be decided by Licensee in consultation with Ipsen.  The commencement, strategies, termination, and settlement of any action or proceedings relating to the validity or suspected or actual Infringement of Licensee Technology, or any portion thereof, shall be decided solely by Licensee without any requirement that Licensee consult with Ipsen.  Any proceedings initiated and pursued by Licensee pursuant to this Section 10.6 shall be at the expense of Licensee.  Nothing in this Agreement, however, shall be deemed to require Licensee to enforce all or any portion of the Ipsen Licensed Technology, Joint Inventions, Joint Patent Rights or Licensee Technology against others; provided, however, that if Licensee does not enforce all or any portion of the Ipsen Licensed Technology, Joint Inventions or Joint Patent Rights, Ipsen may do so at its expense and, if necessary under the relevant law of the concerned jurisdiction, in the name of Licensee as a plaintiff, unless Licensee reasonably believes that pursuit by Ipsen of any such enforcement action jeopardizes all or any portion of the Ipsen Licensed Technology, Joint Inventions or Joint Patent Rights, including the validity thereof, and sends written notice to Ipsen stating that Ipsen should not pursue any such enforcement action for this reason, in which case Ipsen shall not pursue any such enforcement action.  Ipsen may not settle any proceedings or other enforcement action without the prior written consent of Licensee, which consent shall not be unreasonably withheld or delayed.  At the request of the Party bringing such enforcement action or proceeding under this Section 10.6, the other Party shall cooperate reasonably with such Party, including without limitation by having such other Party agree to be named as a party if necessary to such enforcement action or proceeding, and any such reasonable cooperation by such other Party shall be at the sole cost and expense of such Party that requested such cooperation.  The Party not bringing an enforcement action or proceeding under this Section 10.6 with respect to the validity or suspected or actual Infringement of Ipsen Licensed Technology, Joint Inventions or Joint Patent Rights shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense.  Any damages, costs or other amounts recovered in connection with any action or proceeding initiated and pursued by Licensee or Ipsen pursuant to this Section 10.6, including, without limitation, any settlement thereof, in connection with the validity or suspected or actual Infringement of Ipsen Licensed Technology, Joint Inventions or Joint Patent Rights, shall be allocated

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

33

 

CONFIDENTIAL

 

first to [          ]*, and any remaining amounts shall be allocated as follows:  [          ]*.

 

10.7        Third party intellectual property rights

 

10.7.1     Each Party shall give prompt written notice to the other of any intellectual property rights of any third party which could reasonably be considered as constituting impediment on the use of the Ipsen Licensed Technology, Joint Inventions or Joint Patent Rights in accordance with the provisions of this Agreement or on the research, development, manufacture, use, marketing, promotion, distribution, sale, import or export of Licensed Product, in which event the Parties shall agree on the strategy and procedural steps to be taken in respect of opposing and/or settling such potential impediment.

 

10.7.2     Each Party shall give prompt written notice to the other of claims or suits arising out of actual or alleged Infringement of Patent Rights, Know-How or other intellectual property owned by a third party, as a result of any use of the Ipsen Licensed Technology, Joint Inventions or Joint Patent Rights in accordance with the provisions of this Agreement or on the research, development, manufacture, use, marketing, promotion, distribution, sale, import or export of Licensed Product, in which event Licensee, subject to the provisions of Section 10.7.3, shall have the right to contest or defend such claim or suit on behalf of itself and on behalf of Ipsen.  If Licensee elects to contest or defend such claim or suit, Licensee shall notify Ipsen of such election, and shall keep Ipsen fully informed of any development in such claim or suit, including by transmitting copies of all documents in such claim or suit.  If Licensee contests or defends a claim or suit pursuant to this Section 10.7.2 and Ipsen has not elected to contest or defend such claim or suit subject to, and in accordance with, the provisions of Section 10.7.3, then (a) Licensee shall control the defense of such claim or suit, (b) Ipsen shall provide assistance in the defense of such claim or suit in a reasonable and timely manner upon reasonable request of Licensee and at Licensee’ sole cost and expense; and (c) Licensee shall have the right to compromise or settle such claim or suit; provided, however, that, if such claim or suit was originally made or filed against Ipsen or any of its Affliates or pertains to any of the Ipsen Licensed Technology, Joint Patent Rights or Joint Know-How, any such compromise or settlement by Licensee of such claim or suit shall be subject to Ipsen’s prior written approval, which shall not be unreasonably withheld or delayed.  Notwithstanding Licensee’s control of the defense of any claim or proceeding pursuant to this Section 10.7.2, Ipsen shall have the right to participate in such defense using counsel of its own choice and at its own expense, provided that such claim or proceeding was originally made or filed

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

34

 

CONFIDENTIAL

 

against Ipsen or any of its Affiliates or pertains to any of the Ipsen Licensed Technology, Joint Patent Rights or Joint Inventions.

 

10.7.3     If, within [          ]* after Licensee receives written notice of any such claim or suit, Licensee elects not to contest or defend, or fails to notify Ipsen of its intent to contest to or defend, such claim or suit, then Ipsen shall have the right to contest or defend such claim or suit on behalf of itself and Licensee and shall keep Licensee fully informed of any development in such claim or suit, including by transmitting copies of all documents submitted in such claim or suit. Notwithstanding any of the foregoing provisions of this Section 10.7.3 to the contrary, Ipsen’s right under this Section 10.7.3 to contest or defend such claim or suit shall apply only if either (i) such claim or suit was originally made or brought against Ipsen or any of its Affiliates or (ii) such claim or suit pertains to any of the Ipsen Licensed Technology, Joint Patent Rights or Joint Inventions.  If Ipsen contests or defends a claim or suit pursuant to this Section 10.7.3, then (a) Ipsen shall control the defense of such claim or suit, (b) Licensee shall provide assistance in the defense of such claim or suit in a reasonable and timely manner upon reasonable request of Ipsen and at Ipsen’s sole cost and expense and (c) Ipsen shall have the right to compromise or settle such claim or suit; provided, however, that such compromise or settlement shall be subject to Licensee’s prior written approval, which shall not be unreasonably withheld or delayed.  Notwithstanding Ipsen’s control of the defense of any such claim or proceeding, Licensee shall have the right to participate in such defense using counsel of its own choice and at its own expense.

 

10.7.4     The defending Party shall bear its own costs and expenses (including, without limitation, attorneys fees and court costs) in connection with the defense of any claim or suit pursuant to Section 10.7.2 or Section 10.7.3, and the defending Party shall also bear the costs and expenses of the other Party if and to the extent that such costs and expenses were incurred by such other Party in connection with reasonable assistance provided by such other Party in connection with such defense at the request of the defending Party.

 

10.7.5     In the event that, in connection with the defense of any claim or suit pursuant to this Section 10.7 or any settlement thereof, the defending Party shall receive damages, costs or other amounts, such damages, costs or other amounts shall be treated in the manner contemplated under Section 10.6 as if they had been received by the defending Party in connection with any action or proceeding initiated and pursued by the defending Party pursuant to Section 10.6 above.

 

10.7.6     The provisions of this Section 10.7 and the respective rights and obligations of the Parties under this Section 10.7 shall be without prejudice to any of the provisions of Article 15 or any of the respective rights and obligations of the Parties under Article 15.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

35

 

CONFIDENTIAL

 

10.8        Patent Notices.

 

All notices provided under this Article 10 to Licensee shall be given to:

 

Rhythm Pharmaceuticals, Inc.

RHYTHM PHARMACEUTICALS, INC

855 Boylston Street, 11th Floor,

Boston MA 02116

Attn:  Bart Henderson, President

 

with a copy to:

 

Bingham McCutchen LLP

One Federal Street

Boston, Massachusetts U.S.A. 02110

Attn:  Julio E. Vega, Esq.

 

All notices provided under this Article 10 to Ipsen shall be given to:

 

IPSEN PHARMA SAS.

65 Quai Georges Gorse

92100 Boulogne-Billancourt, France

Attn:  Head, Patent Law

 

With a copy to :

 

BIOMEASURE INC.

27 Maple Street

Milford, Massachussetts

01757-3650 USA

Attn : Patent Department

 

ARTICLE 11  CONFIDENTIAL INFORMATION

 

11.1        Non-Disclosure and Non-Use.  In performing under this Agreement, the Parties will share proprietary information (“Confidential Information”) with each other. For the purpose of this Section 11.1, any terms of this Agreement shall be considered as Confidential Information of both Parties. A Party receiving Confidential Information under this Agreement (“Receiver”) from the other disclosing Party (“Discloser”) shall maintain such Confidential Information as follows:

 

The Receiver of a given item of Confidential Information agrees:

 

·                  not to use such Confidential Information for any purpose other than in connection with the purpose of carrying out this Agreement;

 

·     to treat such Confidential Information as it would for its own confidential information of the same nature and importance; and

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

36

 

CONFIDENTIAL

 

·      to take all reasonable precautions to prevent the disclosure of such Confidential Information to any third party without the prior written consent of the Discloser, except to the extent otherwise permitted pursuant to Section 11.3 below.

 

11.2        Exceptions.  A Receiver shall be relieved of any and all obligations under Section 11.1 regarding Confidential Information which:

 

·                  was known to the Receiver or its Affiliates prior to receipt hereunder or under any confidentiality agreements signed prior to the Effective Date between the Parties; or

 

·                  as demonstrated by the Receiver by competent written proof, is independently generated by the Receiver or its Affiliates by persons who have not had access to or knowledge of the Confidential Information disclosed hereunder; or

 

·                  at the time of disclosure by the Discloser to the Receiver, was generally available to the public, or which after disclosure hereunder becomes generally available to the public through no fault attributable to the Receiver, or its Affiliates or sublicensees; or

 

·                  is hereafter made available to the Receiver or its Affiliates for use and unrestricted disclosure by the Receiver from any third party having a right to do so.

 

11.3        Authorized Disclosure.

 

11.3.1     Nothing in this Agreement shall prohibit disclosure by a Receiver of Confidential Information to its (i) Affiliates, directors, employees, consultants, advisors or clinical investigators, (ii) potential or actual sublicensees, Contractors, assignees, lenders or investors, or (iii) other third parties, if any, but in each case only on a strict need to know basis for purposes of (x) carrying out, or causing to be carried out, any of the provisions of this Agreement, (y) the exercise or transfer by such Receiver of any of its rights under this Agreement, and (z) providing for the delegation of any of the obligations of such Receiver under this Agreement; provided, however, that any such person to whom such disclosure is made is bound by confidentiality obligations that are no less stringent than the confidentiality obligations of the Parties under this Article 11 (except that the duration of such confidentiality obligations shall be for a period not to exceed [          ]* from the time of disclosure to such person of Confidential Information).

 

11.3.2     The restrictions set forth in this Article 11 shall not prevent either Party from disclosing any Confidential Information to government agencies to the extent reasonably necessary to file for, prosecute or maintain Patent Rights or to seek Regulatory Approval for any Licensed Product.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

37

 

CONFIDENTIAL

 

The restrictions set forth in this Article 11 shall not prevent disclosure to the extent required by law or pursuant to a judicial or governmental order, provided that the Receiver makes reasonable efforts to minimize the extent of any required disclosure and gives the Discloser sufficient notice to permit the Discloser to seek a protective order or other similar order with respect to such Confidential Information, with Receiver’s reasonable assistance therefor.

 

11.4        Survival.  This Article 11 shall survive any termination or expiration of this Agreement for a period of [          ]*.

 

ARTICLE 12  PUBLICATION AND PRESS RELEASE

 

12.1        Publications.  Neither Party shall publish or publicly present the results of studies carried out under this Agreement to the extent that such publication or such results include information provided to the publishing or presenting Party by the other Party, unless and until the publishing or presenting Party shall have provided the other Party with the opportunity for prior review of such publication or results in accordance with the provisions set forth below in this Section 12.1.  Notwithstanding the foregoing or any other provision to the contrary in this Section 12.1, Ipsen shall not publish or publicly present the results of studies carried out under this Agreement by Licensee, its Affiliates, Sublicensees or Contractors.  For purposes of this Section 12.1, the term “Publication Eligible Material” shall mean any proposed abstracts, manuscripts or presentations (including verbal presentations) that (i) relate to any Licensed Product, (ii) are proposed to be published or publicly presented by either Party and (iii) contain information provided to the publishing or presenting Party by the other Party.  Each Party agrees to provide the other Party the opportunity to review any Publication Eligible Material that such Party proposes to publish or publicly present at least [          ]* prior to their intended submission for publication and agrees, upon request, not to submit or publicly present any such Publication Eligible Material until the other Party is given a reasonable period of time (not to exceed [          ]*) to secure patent protection for any material in such publication or presentation that is owned by the non-publishing Party (either individually or jointly with the publishing Party) and which the non-publishing Party believes to be patentable.  Neither Party shall have the right to publish or publicly present Confidential Information of the other Party, and each Party shall remove the Confidential Information of the other Party from any proposed publication or presentation upon request by such other Party.  Nothing contained in this Section 12.1 shall prohibit the inclusion of information necessary to file a patent application with a government authority, except for Confidential Information of the non-filing Party, provided the non-filing Party is given a reasonable opportunity to review the information to be included prior to submission of such patent application.  Notwithstanding the foregoing, the Parties recognize that independent investigators have been engaged, and will be engaged in the future, to conduct clinical trials of Licensed Products.  Such independent investigators are understood to operate in an academic environment and shall be allowed to release information regarding such studies in a manner consistent with academic standards.  In the event that either Party submits any manuscript or other publication relating to any Licensed Product, it will consider and acknowledge the contributions of the other Party, including, as appropriate, co-authorship.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

38

 

CONFIDENTIAL

 

12.2        Press Release; Public Disclosure of Agreement.  The Parties shall issue a mutually agreed upon joint press release at an agreed date promptly following the execution of this Agreement.  Ipsen and Licensee will jointly discuss and agree in writing on any statement to the public regarding this Agreement or any of its terms, subject in each case to disclosure otherwise required by law or regulation as determined in good faith by each Party.  When a Party elects to make any such statement it will give the other Party at least [          ]* notice to the other Party to review and comment on such statement.

 

12.3        Use of Ipsen’s name. Licensee shall not use Ipsen’s name (or any of the names of Ipsen’s Affiliates) in any communication to third parties, whether oral or written, without Ipsen’s prior written approval.

 

12.4        Non-Disclosure of Termination Event.  In the event of a termination of this Agreement by Licensee under Section 14.3, Licensee will not disclose or cause to be disclosed to any third party the facts or circumstances regarding such termination, except for any such disclosure which is required by law (including if requested by any regulatory agency, taxing authority or commission of competent jurisdiction).  As part of its obligation under this Section 12.4, except as is required by law (including if requested by any regulatory agency, taxing authority or commission of competent jurisdiction), Licensee will not (i) issue any press release with respect to the facts or circumstances regarding termination of this Agreement under Section 14.3 or (ii) respond to press inquiries with respect to the facts or circumstances regarding such termination, other than responses which are materially consistent with public disclosure regarding the same by Ipsen.  For purposes of clarity, nothing in this Section 12.4 shall prevent or restrict Licensee from disclosing or causing to be disclosed publicly or to any third party the fact that Licensee has terminated this Agreement for any reason or no reason if and when such termination has in fact occurred.  In addition, notwithstanding anything express or implied in this Section 12.4 to the contrary, Licensee shall be free to disclose the facts or circumstances regarding any termination of this Agreement by Licensee under Section 14.3 to any third party to whom Licensee is entitled to disclose Confidential Information of Ipsen pursuant to Section 11.3 (it being understood that, for purposes of this sentence and the provisions of Section 11.3, such facts and circumstances shall be treated as Confidential Information of Ipsen).

 

ARTICLE 13  REPRESENTATIONS, WARRANTIES AND COVENANTS

 

13.1        Mutual Representations and Warranties.  Each Party hereby represents and warrants as follows:

 

(a)                                 It is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including, without limitation, the right to grant the licenses it is granting hereunder.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

39

 

CONFIDENTIAL

 

(b)                                 On the Effective Date, (i) it has the full right and authority to enter into this Agreement and perform its obligations hereunder, (ii) it is not aware of any impediment that would prevent it from entering into the Agreement or that would inhibit its ability to perform its obligations under this Agreement, (iii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder, and (iv) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance with its terms.

 

(c)                                  It has not entered into any agreement with any third party that is in conflict with the rights granted to the other Party under this Agreement, and has not taken any action that would in any way prevent it from granting the rights granted to the other Party under this Agreement, or that would otherwise materially conflict with or materially adversely affect the rights granted to the other Party under this Agreement.  Its performance and execution of this Agreement will not result in a breach of any other contract to which it is a party.

 

(d)                                 On the Effective Date, it is not aware of any action, suit, inquiry or investigation instituted by any third party that questions or threatens the validity of this Agreement.

 

(e)                                  All necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to be obtained by such Party in connection with the execution, delivery and performance of this Agreement have been obtained.

 

(f)                                   To the best of its knowledge, each Party has, on the Effective Date, the right to grant to the other Party the rights and licenses granted by such Party to the other Party pursuant to this Agreement.

 

(g)                                  Each Party has, on the Effective Date, the necessary qualified personnel, equipment, technical know-how and other means to perform its duties under this Agreement in a timely manner in accordance with the terms hereof.

 

13.2        Ipsen Representations and Warranties.  Ipsen warrants and represents that:

 

(a)                                 Ipsen is the owner of the Ipsen Technology that exists on the Effective Date, free and clear (on the Effective Date) of all liens or security interests. On the Effective Date, neither Ipsen nor any of its Affiliates is aware of any right or license of any third party that is required and has not been obtained by Ipsen to permit Ipsen to perform its obligations under this Agreement in accordance with the terms of this Agreement or to

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

40

 

CONFIDENTIAL

 

permit Licensee to exercise its rights hereunder in accordance with the terms of this Agreement.

 

(b)                                 On the Effective Date, Ipsen is the co-owner of the [        ]* Patent Application, free and clear of all liens or security interests.

 

(c)                                  On the Effective Date, neither Ipsen nor any of its Affiliates owns, controls or otherwise has the right to use or practice any rights under any patent or patent application that are not included in the Ipsen Patent Rights on the Effective Date and that would be necessary to the research, Development, manufacture, marketing, promotion, use, sale, import or export of Licensed Products.

 

(d)                                 On or prior to the Effective Date, neither Ipsen nor any of its Affiliates has received notice from any third party of the existence or pendency of any claims asserting that the Ipsen Licensed Technology Infringes the rights of any third party.

 

(e)                                  On or prior to the Effective Date, neither Ipsen nor any of its Affiliates has given any notice to any third party asserting Infringement by such third party of all or any portion of the Ipsen Licensed Technology and neither Ipsen nor any of its Affiliates is not aware (without conducting any special investigation for purposes of making this representation and warranty) of any such Infringement.

 

(f)                                   On the Effective Date, neither Ipsen nor any of its Affiliates is a party to any contract or agreement with a third party (other than [          ]* with respect to the Ipsen [          ]* Patent Rights) pursuant to which Ipsen or any of its Affiliates licensed-in or otherwise acquired or has the right to use the Ipsen Licensed Technology.  Neither Ipsen nor any of its Affiliates is on the Effective Date, or will become at any time during the Term, a party to any contract or agreement with a third party pursuant to which Licensee (or any of Licensee’s Affiliates, Sublicensees or Contractors) is or will be required to make payments on account of the use, practice or exploitation of all or any portion of the Ipsen Licensed Technology.

 

(g)                                  Ipsen has disclosed to Licensee (i) the results of all preclinical and clinical testing in the possession or control of Ipsen or any of its Affiliates or that are known to Ipsen or any of its Affiliates on the Effective Date; and (ii) all information in the possession or control of Ipsen or any of its Affiliates or that is known to Ipsen or any of its Affiliates on the Effective Date concerning [          ]*.  Ipsen has not withheld any information that, in Ipsen’s reasonable judgment, is material to this transaction.  All information and data disclosed by Ipsen to Licensee are complete and accurate in all material respects.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

41

 

CONFIDENTIAL

 

(h)                                 On the Effective Date, there is no litigation pending or, to the knowledge of Ipsen and its Affiliates, threatened against Ipsen or any of its Affiliates with respect to all or any portion of the Ipsen Licensed Technology.

 

(i)                                     On or prior to the Effective Date, neither Ipsen nor any of its Affiliates has entered into any agreement with a third party pursuant to which Ipsen or any of its Affiliates shall have agreed not to enforce any right of Ipsen or any of its Affiliates to preclude such third party from using or practicing any or all of the Ipsen Licensed Technology.

 

(j)                                    Except for the Patent Rights set forth on Appendix A, as of the date of this Agreement, neither Ipsen nor any of its Affiliates own or Control as of the date of this Agreement, or will own or Control at any time after the date of this Agreement, any Patents Rights that claim any Ipsen Ghrelin Program Invention.

 

(k)                                 That the representation set forth in Section 13.2(j) of the Original Agreement was true and correct as of the Effective Date.

 

13.3        Licensee Representations and Warranties.  Licensee warrants and represents that as of the Effective Date, Licensee did not knowingly withhold any material information related to the Ipsen Patent Rights with regards to third party intellectual property rights.

 

13.4        No Other Representations or Warranties.  EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT OR IN ANY OTHER WRITTEN AGREEMENT BETWEEN THE PARTIES, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF, AND EACH PARTY EXPRESSLY DISCLAIMS, ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF DESIGN, MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE.

 

13.5        Mutual Covenants.  Each Party covenants the following:

 

(a)                                 That it shall comply in all material respects with all federal, state, provincial, territorial, governmental and local laws, rules and regulations applicable to the development, manufacture and commercialization of Licensed Products by such Party.

 

(b)                                 That it shall disclose immediately to the other Party all information in its possession or control and as to which it becomes aware concerning side effects, injury, toxicity or sensitivity reaction and incidents or severity thereof with respect to Licensed Products.

 

ARTICLE 14  TERM AND TERMINATION

 

14.1        Term.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

42

 

CONFIDENTIAL

 

This Agreement is entered into for a period commencing on the Effective Date and, unless this Agreement is terminated sooner as provided in this Article 14, ending, on a country-by-country basis and on a Licensed Product-by-Licensed Product basis, on the expiration of the applicable Royalty Term (the “Term”).  Upon expiration of the Term of this Agreement, the Licensed Rights granted by Ipsen to Licensee pursuant to Section 2.1 hereof, to the extent they remain in full force and effect at the time of such expiration, shall thereafter become irrevocable, perpetual and fully paid-up exclusive licenses and shall survive such expiration of the Term of this Agreement.

 

14.2        Breach.  A Party (“Non-Breaching Party”) shall have the right, in addition to any other rights and remedies, to terminate this Agreement in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement.  The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach.  The Breaching Party shall have a period of [          ]* after such written notice is provided to cure such breach.  If such breach is not cured within the relevant period, this Agreement shall terminate.  The waiver by either Party of any breach of any term or condition of this Agreement shall not be deemed a waiver as to any subsequent or similar breach.  The right to terminate this Agreement under this Section 14.2 is in addition to any other right and protection that may otherwise be available as a result of a breach, including, without limitation, the right to damages.

 

14.3        Voluntary Termination.  Licensee may terminate the Agreement for any reason or no reason (including, without limitation, any decision by Licensee to discontinue Development) and at any time by giving Ipsen one hundred eighty (180) days prior written notice. Such 180 day notice period may be reduced by Ipsen, on a Licensed Product-by Licensed Product basis, in the event Ipsen has identified a new licensee for one or more Licensed Products before the expiration of such 180 day notice period.

 

14.4        Ipsen Right to Voluntarily Terminate.

 

14.4.1     Ipsen shall have the unilateral right to terminate this Agreement in its entirety, upon [          ]*, if Licensee, its Affiliates or Sublicensees in any country of the world brings an action or proceeding seeking to have an Ipsen License Patent Right declared invalid or unenforceable.

 

14.4.2     In case that Licensee does not Develop a Licensed Product or does not continue the Development of a Licensed Product already in Development, in either case both directly and indirectly (through an Affiliate, Sublicensee or Contractor), then Licensee shall so inform Ipsen and Ipsen shall have the unilateral right to terminate this Agreement with respect to such Licensed Product upon [          ]*.  In the event of early termination of this Agreement with respect to any Licensed Product pursuant to this Section 14.4.2, (A) all Licensed Rights granted by Ipsen to Licensee pursuant to Section 2.1 hereof with respect to such Licensed Product shall terminate and Ipsen Licensed Know-How and Ipsen Licensed Patent Rights with respect to such Licensed Product shall revert back to Ipsen at no cost to Ipsen and (B) all

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

43

 

CONFIDENTIAL

 

Licensee IP (as defined in Section 14.6 hereof) with respect, and to the extent it pertains, to such Licensed Product shall be licensed to Ipsen or its designee, at Ipsen’s request, pursuant to a written agreement to be negotiated in good faith by the Parties whereby Ipsen will compensate Licensee for such license of Licensee IP.   Any such written agreement shall also provide that Ipsen will assume any and all obligations of Licensee to third parties relating to such Licensee IP.  In the event the Parties cannot reach an agreement on the terms of such written agreement, the Parties agree to refer this matter to arbitration as per Article 16.  Notwithstanding anything express or implied in this Section 14.4.2 to the contrary, the parties agree that, so long as Licensee is actively engaged in finding a partner or Sublicensee to Develop any Licensed Product or to continue Development of any Licensed Product already in Development and can make the reasonable demonstration of such active out-licensing activities, the provisions of this Section 14.4.2 shall not be applicable to such Licensed Product.

 

14.5        Bankruptcy. Except if and to the extent otherwise provided under applicable law, either Party shall have the right to terminate this Agreement upon [          ]* if such other Party is generally unable to meet its debts when due, or makes a general assignment for the benefit of its creditors, or there shall have been appointed a receiver, trustee or other custodian for such other Party for all or a substantial part of its assets, or any case or proceeding shall have been commenced or other action taken by or against such other Party in bankruptcy or seeking the reorganization, liquidation, dissolution or winding-up of such other Party or any other relief under any bankruptcy, insolvency, reorganization or other similar act or law, and any such event shall have continued for [        ]* undismissed, unstayed, unbonded and undischarged.  Any termination of this Agreement pursuant to this Section 14.5 shall be effective [          ]*.

 

14.6        Consequences of Early Termination. In any event of early termination of this Agreement other than due to early termination by Licensee on account of material breach by Ipsen of any of its obligations under this Agreement, (A) all Licensed Rights granted by Ipsen to Licensee pursuant to Section 2.1 hereof shall terminate and Ipsen Licensed Know-How and Ipsen Licensed Patent Rights shall revert back to Ipsen at no cost for Ipsen and (B) all Licensee Know-How, Licensee Patent Rights and Licensee Joint Technology including without limitation preclinical, clinical and manufacturing data and improvements of Licensee with respect to Licensed Products, as well as all of the then ongoing development activities and manufacturing Know-How with respect to any Licensed Product (“Licensee IP”), shall be licensed to Ipsen or its designee, at Ipsen’s request, pursuant to a written agreement to be negotiated in good faith by the Parties whereby Ipsen will compensate Licensee for such license of Licensee IP.  Any such written agreement shall also provide that Ipsen will assume any and all obligations of Licensee to third parties relating to such Licensee IP.  In the event the Parties cannot reach an agreement on the terms of such written agreement, the Parties agree to refer this matter to arbitration as per Article 16.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

44

 

CONFIDENTIAL

 

14.7        Other Consequences of Early Termination. Upon termination of this Agreement:

 

14.7.1     Licensee shall:

 

14.7.1.1  make its personnel reasonably available to Ipsen as necessary to effect an orderly transition of development and commercial responsibilities, with the reasonable cost of such personnel to be borne by Ipsen for such services; and

 

14.7.1.2  assign and transfer to Ipsen, and execute all such documents as may be reasonably required to transfer hereunder, all of Licensee’s right, title and interest in the following to the extent they pertain to Licensed Products:

 

-                    all regulatory filings (such as INDs), Regulatory Approvals, clinical trial agreements (to the extent assignable and not cancelled), provided however that the responsibility for interacting with the applicable regulatory authorities in connection with the assignment and transfer of such regulatory filings, Regulatory Approvals and clinical trial agreements and the preparation of the documentation necessary to such assignment and transfer shall be Ipsen’s; and

 

-                    all customer lists, marketing and promotional material, and all other documentation related to marketing, sale, and promotion of the Licensed Product in the Territory, and

 

-                    all trademarks used for Licensed Product, provided however that the responsibility of preparing and filing of the documents for the recordation of the assignments with the competent authorities in each applicable country and any action required ancillary, shall be borne by Ipsen and that each Party shall bear its expenses caused by its activities in connection with the assignments and transfer of the trademarks.

 

14.7.1.3  subject to, and in accordance with, the provisions of Section 14.6 hereof regarding Licensee IP, assign and transfer to Ipsen, and execute all such documents as may be reasonably required to transfer hereunder, all of Licensee’s right, title and interest in the following to the extent they pertain to Licensed Product:

 

·                  all drug master files and related manufacturing data in connection with Licensed Product; and

 

·                  all data, including formulation data, results, clinical trial data, support documentation having arisen out of the materials and other information, in Licensee’s possession and control related to Licensed Product in the Territory.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

45

 

CONFIDENTIAL

 

14.7.2     subject to, and in accordance with, the provisions of Section 14.6 hereof regarding Licensee IP, Licensee shall initiate transfer (and complete the same in a timely manner), to Ipsen of all technical and industrial know how related to the manufacturing of Licensed Product for use by Ipsen and shall provide reasonable assistance and support (up to a reasonable number of person-days of qualified personnel) as may be reasonably required by Ipsen to be in a position to make Licensed Product itself.  Any such transfer under this Section 14.7.2 shall be at Ipsen’s expense except in the case of early termination of this Agreement resulting from Licensee’s material breach in which case any such transfer shall be at Licensee’s sole cost and expense.

 

14.7.3     All licenses granted by Ipsen to Licensee under this Agreement shall terminate on the effective date of termination.  Notwithstanding anything in this Section 10.7.3 or elsewhere in this Agreement to the contrary, Ipsen may authorize Licensee for a period not exceeding [          ]* to continue making, marketing, promoting and selling Licensed Product in the Territory after the termination of such licenses.

 

14.7.4     No compensation or refund shall be due by either Party to the other Party, otherwise than damages as determined by a court of competent jurisdiction and compensation that may be due by Ipsen to Licensee as contemplated under Section 14.6.

 

14.7.5     Licensee shall agree to take such actions and execute such instruments, agreements and documents as are necessary to effect the foregoing.

 

14.7.6     Unless otherwise agreed by the Parties, the termination of this Agreement shall cause the automatic termination of all ancillary agreements related hereto, including, but not limited to, the Clinical Supply Agreements.

 

14.8        Survival of Sublicenses.  Notwithstanding anything express or implied in this Article 14 or elsewhere in this Agreement to the contrary, each Sublicense Agreement shall survive any termination of this Agreement and shall continue in full force and effect in accordance with the respective terms thereof, provided that (i) the applicable Sublicensee shall not be in material breach of such Sublicense Agreement and (ii) the terms of such Sublicense Agreement permit Ipsen to replace Licensee as a party under such Sublicense Agreement upon any such termination of this Agreement and that such Sublicense Agreement and its terms conform with all of the requirements therefor set forth in this Agreement.

 

14.9        Accrued Rights; Surviving Rights and Obligations.  Expiration or termination of this Agreement, for any reason, will not relieve either Party of any obligation accruing prior to such expiration or termination.  Articles 1, 11, 12, 13, 14, 15, 16 and 17 and Section 5.6 shall survive expiration or termination of this Agreement. In addition, the obligations and rights of any other provisions of this Agreement, which by their nature of the provision and the nature of the termination or expiration, are intended to survive, shall survive and continue to be enforceable.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

46

 

CONFIDENTIAL

 

ARTICLE 15  INDEMNIFICATION

 

15.1        Indemnification by Ipsen.  Ipsen agrees to indemnify, hold harmless and defend Licensee and its Affiliates and their respective directors, officers, employees and agents (collectively, the “Licensee Indemnitees”) from and against any and all suits, claims, actions, demands, liabilities, expenses and/or loss, cost of defense (including without limitation reasonable attorneys’ fees, court costs, witness fees, damages, judgements, fines and amounts paid in settlement) and any other amounts (collectively, “Losses”) that any Licensee Indemnitee becomes legally obligated to pay to a third party, because of any claim or claims against such Licensee Indemnitee to the extent that such claim or claims arise out of or resulted from (i) a material breach of a representation or warranty or covenant by Ipsen under Article 13; (ii) a material breach by Ipsen of any of its obligations under this Agreement or the Clinical Supply Agreements; (iii) the manufacture by or on behalf of Ipsen of any Licensed Product and the supply thereof to Licensee or any of its Affiliates, Sublicensees or Contractors pursuant to this Agreement or the Clinical Supply Agreements; (iv) the use, research, or handling of any Licensed Product, by or on behalf of Ipsen or any of its Affiliates, licensees, sublicensees, distributors or contractors, or any of their respective employees or agents; or (iv) the gross negligence or willful misconduct of Ipsen or any of its Affiliates or contractors, or any of their respective employees or agents; provided, however, that Ipsen shall not be required to indemnify the Licensee Indemnitees for any Losses pursuant to this Section 15.1 to the extent that (1) such Losses arise from Licensee’s material breach of any of its obligations under this Agreement or the Clinical Supply Agreements, (2) such Losses arise or result from the gross negligence or willful misconduct of Licensee or any of its Affiliates or Contractors, or any of their respective employees or agents, or (3) Ipsen’s liability for such Losses is limited pursuant to Section 5.4.

 

15.2        Indemnification by Licensee.  Licensee agrees to indemnify, hold harmless and defend Ipsen and its Affiliates and their respective directors, officers, employees and agents (collectively, the “Ipsen Indemnitees”) from and against any and all Losses that any Ipsen Indemnitee becomes legally obligated to pay to a third party, because of any claim or claims against such Ipsen Indemnitee to the extent that such claim or claims arise out of or resulted from (i) a material breach of a representation or warranty or covenant by Licensee under Article 13, (ii) a material breach by Licensee of any of its obligations under this Agreement  or the Clinical Supply Agreements, (iii) the making, use, research, development, handling or commercialization of any Licensed Product by or on behalf of Licensee or any of its Affiliates, Sublicensees or Contractors, or any of their respective employees or agents or (v) the gross negligence or willful misconduct of Licensee or its Affiliates or Contractors, or any of their respective employees or agents; provided, however, that Licensee shall not be required to indemnify the Ipsen Indemnitees for any Losses pursuant to this Section 15.2 to the extent that (1) such Losses arise from Ipsen’s material breach of any of its obligations under this Agreement or the Clinical Supply Agreements, (2) such Losses arise or result from the gross negligence or willful misconduct of Ipsen or any of its Affiliates or contractors, or any of their respective agents or employees, (3) such Losses arise or result from the manufacture and supply of Licensed Product by or on behalf of Ipsen pursuant to this Agreement or the Clinical Supply Agreements, (4) such Losses arise or result from any

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

47

 

CONFIDENTIAL

 

Infringement of the patent rights or other intellectual property rights of any third party as a result of the use or practice of Ipsen Licensed Technology by Licensee or any of its Affiliates, Sublicensees or Contractors in accordance with the provisions of this Agreement or (5) Licensee’s liability for such Losses is limited pursuant to Section 15.4.

 

15.3        Procedure.  In the event of a claim by a third party against any person entitled to indemnification under this Agreement (“Indemnified Person”), the Indemnified Person shall promptly notify the Party having the indemnification obligation under this Agreement with respect to such claim (such Party, the “Indemnifying Party”) in writing of the claim.  The indemnifying Party shall have the right to assume the defense of any such third party claim for which it is obligated to indemnify the Indemnified Person under this Article 15.  The Indemnified Person shall cooperate with the Indemnifying Party (and its insurer) as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s sole cost and expense.  The Indemnified Person shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party.  The Indemnifying Party shall have no obligation to indemnify an Indemnified Person in connection with any settlement made without the Indemnifying Party’s prior written consent.  If the Parties cannot agree as to the application of this Article 15 to any third party claim, the Parties may conduct separate defenses of such claims, with each Party retaining the right to claim indemnification from the other in accordance with this Article 15 upon resolution of the underlying claim.

 

15.4        NOTWITHSTANDING ANYTHING EXPRESS OR IMPLIED IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR [          ]* ARISING OUT OF THIS AGREEMENT.

 

ARTICLE 16  DISPUTE RESOLUTION AND GOVERNING LAW

 

16.1        Disputes.  Unless otherwise set forth in this Agreement, in the event of a dispute arising under this Agreement between the Parties, the Parties shall remain bound by the terms of this Agreement and each Party shall refer such dispute to one executive officer, and such executive officer shall attempt in good faith to resolve such dispute.

 

16.2        Arbitration.  If the Parties are unable to resolve a given dispute pursuant to Section 16.1 within [          ]* of referring such dispute to the executive officers, the Parties shall remain bound by the terms of this Agreement and either Party may have the given dispute settled by binding arbitration in the manner described below:

 

16.3        Arbitration Request.  If a Party intends to begin an arbitration to resolve a dispute arising under this Agreement, such Party shall provide written notice (the “Arbitration Request”) to the other Party of such intention and the issues for resolution.

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

48

 

CONFIDENTIAL

 

16.4        Additional Issues.  Within [          ]* after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolution.

 

16.5        Arbitration Procedure.  Any arbitration to resolve a dispute arising under this Agreement shall be a final and binding arbitration pursuant to the then-current Rules of Arbitration of the International Chamber of Commerce as hereinafter provided:

 

16.5.1     The Arbitration Tribunal shall consist of three (3) arbitrators. Each party shall nominate one (1) arbitrator and the two (2) arbitrators so named will then jointly appoint the third arbitrator as chairman of the Arbitration Tribunal. If one Party fails to nominate its arbitrator or, if the parties’ arbitrators cannot agree on the person to be named as chairman within [          ]*, the International Chamber of Commerce shall make the necessary appointments for arbitrator or chairman in accordance with the Rules of Arbitration of the International Chamber of Commerce.

 

16.5.2     The place of arbitration shall be in London, England, and the arbitration proceedings shall be held in English. The procedural law of the place of arbitration shall apply where the said Rules are silent.

 

16.5.3     The award of the Arbitration Tribunal shall be final and judgment upon such an award may be entered in any competent court or application may be made to any competent court for juridical acceptance of such an award and order of enforcement.

 

16.5.4     Notwithstanding the referral of any dispute, controversy or claim arising out of or in connection with this Agreement to arbitration pursuant to this Section 16.5, both Parties shall remain free to seek interim, injunctive or conservatory relief, provided that the order of the relevant judicial authority shall not in any way prejudice the above tribunals’ power to settle the dispute referred to them in accordance with the Rules of Arbitration of the International Chamber of Commerce.

 

16.6        Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of New York, U.S.A., without reference to its choice of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention).

 

ARTICLE 17  MISCELLANEOUS

 

17.1        Agency - Independent Contractor.  Neither Party is an employee, agent or representative of the other Party for any purpose, and this Agreement shall not create or establish an employment, agency or any other relationship.  Except as may be specifically provided herein, neither Party shall have any right, power, or authority, nor shall they represent themselves as having authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose.  The Parties agree that the

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

49

 

CONFIDENTIAL

 

relationship of Ipsen and Licensee established by this Agreement is that of independent licensee and licensor.  This Agreement does not, is not intended to, and shall not be construed to, establish a partnership or joint venture.

 

17.2        Entire Agreement.  This Agreement, including all appendices, schedules and attachments, embodies the entire understanding of the Parties with respect to the subject matter hereof and supersedes all previous communications, representations or understandings, and agreements, whether oral or written, between the Parties relating to the subject matter hereof.

 

17.3        Assignment.  Except to the extent otherwise expressly provided elsewhere in this Agreement, either Party may assign this Agreement or any of such Party’s rights and obligations under this Agreement to any of its Affiliates or any third party, provided that the rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Parties and that an assignment or delegation of this Agreement by a Party or of any of a Party’s obligations under this Agreement shall not operate to release such Party from any of its obligations under this Agreement or from the specific obligation assigned or delegated by such Party.  Any assignment not in accordance with this Agreement shall be void.

 

17.4        Notices.  Any notice or other communication under this Agreement, unless otherwise specified, shall be in writing and provided when delivered to the addressee at the address listed below (a) on the date of delivery if delivered in person or (b) three (3) days after mailing to the other Party by express mail or overnight delivery service, which obtains a signed receipt:

 

In the case of Ipsen:

 

IPSEN PHARMA SAS

65 Quai Georges Gorse

92100 Boulogne Billancourt - FRANCE

Attn.:  General Counsel

 

In the case of Licensee:

 

Rhythm Pharmaceuticals, Inc.

RHYTHM PHARMACEUTICALS, INC

855 Boylston Street, 11th Floor,

Boston MA 02116

Attn:  M. Bart Henderson — President

 

with a copy to:

 

Bingham McCutchen LLP

One Federal Street

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

50

 

CONFIDENTIAL

 

Boston, Massachusetts U.S.A. 02110

Attn:  Julio E. Vega, Esq.

 

Either Party may change its address for communications by a notice in writing to the other Party in accordance with this Section.

 

17.5        Force Majeure.  Any prevention, delay or interruption of performance (collectively “Delay”) by any Party under this Agreement shall not be a breach of this Agreement if and to the extent caused by occurrences beyond the reasonable control of the Party affected by the force majeure, including but not limited to acts of God, embargoes, governmental restrictions, terrorism, general strike, fire, flood, earthquake, explosion, riots, wars (declared or undeclared), civil disorder, rebellion or sabotage.  The affected Party shall immediately notify the other Party upon the commencement and end of the Delay.  During the Delay, any time for performance hereunder by either Party shall be extended by the actual time of Delay. If the Delay resulting from the force majeure exceeds [          ]*, the other Party, upon written notice to the affected Party, may elect to (a) treat such Delay as a material breach solely for purposes of exercising the right to terminate this Agreement for material breach pursuant to, and in accordance with, Section 14.2, or (b) extend the term of this Agreement for an amount of time equal to the Delay.

 

17.6        Severability.  If any of the provisions of this Agreement are held to be void or unenforceable by a court of competent jurisdiction, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions which will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions.

 

17.7        No Right to Use Names.  Except as otherwise expressly provided herein, this Agreement provides no grant of right to a Party, express or implied, to use in any manner the housemarks or trademarks of the other Party or its Affiliates.

 

17.8        Bankruptcy.  All rights and licenses granted under or pursuant to this Agreement by Ipsen are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (or the equivalent provisions, if any, in the bankruptcy laws of the applicable jurisdiction) licenses of rights to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code.

 

17.9        Legal and Administrative Obligations. In conducting its obligations under this Agreement, each Party shall observe any and all applicable laws and regulations of the Territory, with respect to the development, manufacture, warehousing, promotion, distribution and sale of [          ]*, and undertakes to make and fulfill any and all formalities in connection with all such activities which may be required under applicable laws and regulations of the Territory. In conducting its obligations under this Agreement, each party further agrees to comply in all means with the current

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

51

 

CONFIDENTIAL

 

applicable Good Clinical Practices, Good Manufacturing Practices and Good Distribution Practices and apply a high standard of ethics. In particular, each Party undertakes to comply with the principles set forth in the OECD (Organization for Economic Co-operation and Development) Convention on Combating Bribery of Foreign Public Officials in International Business Transactions while performing its activities within the scope of this Agreement.

 

17.10      Performance by Affiliates.  Each of Licensee and Ipsen acknowledge that obligations under this Agreement may be performed by Affiliates of Licensee and Ipsen.  Each of Licensee and Ipsen guarantee and warrant any performance of this Agreement by its Affiliates.  Wherever in this Agreement the Parties delegate responsibility to Affiliates, the Parties agree that such entities may not make decisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way.

 

17.11      Counterparts.  The Parties may execute this Agreement in counterparts, each of which the Parties shall deem an original, but all of which together shall constitute one and the same instrument.

 

17.12      Waiver.  A waiver of any default, breach or non-compliance under this Agreement is not effective unless signed by the Party to be bound by the waiver.  No waiver will be inferred from or implied by any failure to act or delay in acting by a Party in respect of any default, breach, non-observance or by anything done or omitted to be done by the other Party.  The waiver by a Party of any default, breach or non-compliance under this Agreement will not operate as a waiver of that Party’s rights under this Agreement in respect of any continuing or subsequent default, breach or non-compliance (whether of the same or any other nature).

 

[Remainder of This Page Intentionally Left Blank]

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

52

 

CONFIDENTIAL

 

IN WITNESS WHEREOF, the Parties have executed this Agreement by their proper officers as of the date and year first above written.

 

	
IPSEN PHARMA S.A.S.
    	
 
    	
RHYTHM PHARMACEUTICALS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/   Pierre Boulud
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Pierre   Boulud
    	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
EVP   Corporate Strategy and Managing Director
    	
 
    	
Title:
    	
 
    

 

[Signature Page to Ipsen/Ghrelin License Agreement]

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

CONFIDENTIAL

 

IN WITNESS WHEREOF, the Parties have executed this Agreement by their proper officers as of the date and year first above written.

 

	
IPSEN PHARMA S.A.S.
    	
 
    	
RHYTHM PHARMACEUTICALS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
/s/   Keith Gottesdiener
    
	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
 
    	
 
    	
Name:
    	
Keith   Gottesdiener
    
	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
 
    	
 
    	
Title:
    	
CEO
    

 

[Signature Page to Ipsen/Ghrelin License Agreement]

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

CONFIDENTIAL

 

APPENDIX A — IPSEN Ghrelin Patent Rights as of January 30, 2013

 

[          ]*

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

CONFIDENTIAL

 

APPENDIX B-IPSEN ONGOING PRE-CLINICAL STUDIES

 

[          ]*

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

CONFIDENTIAL

 

APPENDIX C — INITIAL DEVELOPMENT PLAN

 

Rhythm Pharmaceuticals

 

Clinical Development Plan

 

[                    ]*

 

[                            ]*

 

* CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]